-- SQL dump for selected bioone public tables
-- Generated at 2026-06-19T01:38:12.910Z
-- Tables: public.quote, public.product_category, public.product, public.blog

BEGIN;

SET session_replication_role = replica;

-- ============================================================
-- public.quote
-- ============================================================
DROP TABLE IF EXISTS public."quote" CASCADE;
CREATE TABLE IF NOT EXISTS public."quote" (
    "id" bigint NOT NULL,
    "external_id" character varying(64),
    "first_name" character varying(100) NOT NULL,
    "last_name" character varying(100) NOT NULL,
    "email" character varying(255) NOT NULL,
    "phone" character varying(50),
    "company" character varying(255),
    "department" character varying(255),
    "service_type" character varying(100),
    "timeline" character varying(255),
    "budget" character varying(255),
    "project_description" text,
    "additional_info" text,
    "created_at" timestamp with time zone DEFAULT now() NOT NULL,
    "read" boolean DEFAULT false NOT NULL,
    CONSTRAINT "quote_pkey" PRIMARY KEY (id)
);

INSERT INTO public."quote" ("id", "external_id", "first_name", "last_name", "email", "phone", "company", "department", "service_type", "timeline", "budget", "project_description", "additional_info", "created_at", "read") VALUES
    ('1', 'q_1771961897727', 'Hao', 'Feng', 'Hao@skyangbio.com', '', 'Skyang Bio', '', 'celllines', '', '', 'Looking for CRISPR knockout cell line service', 'Is your cell line service in US?', '2026-02-24T19:38:17.727Z', TRUE);

SELECT setval(pg_get_serial_sequence('public.quote', 'id'), COALESCE((SELECT MAX("id") FROM public."quote"), 1), true);

-- ============================================================
-- public.product_category
-- ============================================================
DROP TABLE IF EXISTS public."product_category" CASCADE;
CREATE TABLE IF NOT EXISTS public."product_category" (
    "category_id" integer NOT NULL,
    "category_name" character varying NOT NULL,
    "description" character varying,
    "priority" integer NOT NULL,
    "external_id" character varying(100),
    "product_type" character varying(50),
    CONSTRAINT "product_category_category_name_key" UNIQUE (category_name),
    CONSTRAINT "product_category_pkey" PRIMARY KEY (category_id)
);

INSERT INTO public."product_category" ("category_id", "category_name", "description", "priority", "external_id", "product_type") VALUES
    (5, 'Cell Lines', NULL, 6, 'stable-cell-lines', 'both'),
    (6, 'Genome Editing', NULL, 1, 'genome-editing', 'both'),
    (7, 'Virus Product', NULL, 5, 'lentivirus', 'both'),
    (8, 'Vector Stock', NULL, 2, 'vector-clones', 'both'),
    (9, 'IVT mRNA', NULL, 3, 'category-1764975611348', 'both'),
    (10, 'Purified Protein', NULL, 4, 'category-1764975769330', 'both');

CREATE INDEX product_category_category_name_670b01bc_like ON public.product_category USING btree (category_name varchar_pattern_ops);
SELECT setval(pg_get_serial_sequence('public.product_category', 'category_id'), COALESCE((SELECT MAX("category_id") FROM public."product_category"), 1), true);

-- ============================================================
-- public.product
-- ============================================================
DROP TABLE IF EXISTS public."product" CASCADE;
CREATE TABLE IF NOT EXISTS public."product" (
    "product_id" bigint NOT NULL,
    "external_id" character varying(100) NOT NULL,
    "product_name" character varying(255) NOT NULL,
    "description" text,
    "image_url" text,
    "product_link" text,
    "category_external_id" character varying(100),
    "product_group" character varying(100),
    "source_type" character varying(50),
    "display_order" integer,
    "source_created_at_ms" bigint,
    "source_created_at" timestamp with time zone,
    "catalog_number" character varying(100),
    "availability" character varying(100),
    "list_price" character varying(100),
    "price_range" character varying(100),
    "quote_only" boolean DEFAULT false NOT NULL,
    "is_featured" boolean DEFAULT false NOT NULL,
    "show_in_featured" boolean DEFAULT false NOT NULL,
    "show_in_gene_editing" boolean DEFAULT false NOT NULL,
    "key_features" text[] DEFAULT ARRAY[]::text[] NOT NULL,
    "options" text[] DEFAULT ARRAY[]::text[] NOT NULL,
    "option_prices" jsonb DEFAULT '{}'::jsonb NOT NULL,
    "storage_stability" text,
    "performance_data" text,
    "data_description" text,
    "manuals" text[] DEFAULT ARRAY[]::text[] NOT NULL,
    "manual_urls" text[] DEFAULT ARRAY[]::text[] NOT NULL,
    "images" text[] DEFAULT ARRAY[]::text[] NOT NULL,
    "store_link" text,
    "content_text" text,
    "hidden" boolean DEFAULT false NOT NULL,
    "raw_product" jsonb,
    "raw_override" jsonb,
    "raw_detail" jsonb,
    "created_at" timestamp with time zone DEFAULT now() NOT NULL,
    "updated_at" timestamp with time zone DEFAULT now() NOT NULL,
    CONSTRAINT "product_external_id_key" UNIQUE (external_id),
    CONSTRAINT "product_pkey" PRIMARY KEY (product_id)
);

INSERT INTO public."product" ("product_id", "external_id", "product_name", "description", "image_url", "product_link", "category_external_id", "product_group", "source_type", "display_order", "source_created_at_ms", "source_created_at", "catalog_number", "availability", "list_price", "price_range", "quote_only", "is_featured", "show_in_featured", "show_in_gene_editing", "key_features", "options", "option_prices", "storage_stability", "performance_data", "data_description", "manuals", "manual_urls", "images", "store_link", "content_text", "hidden", "raw_product", "raw_override", "raw_detail", "created_at", "updated_at") VALUES
    ('1', 'custom-1757608878053', 'custom-1757608878053', NULL, '/images/products/1-BSY3320_2__SYBR_Green_qPCR_Master_Mix-300x300.jpg', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '', 'In Stock', '', NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', NULL, ARRAY[], ARRAY[], ARRAY['/images/products/1-BSY3320_2__SYBR_Green_qPCR_Master_Mix-300x300.jpg'], '', '', FALSE, '{"id":"custom-1757608878053"}'::jsonb, NULL, '{"images":["/images/products/1-BSY3320_2__SYBR_Green_qPCR_Master_Mix-300x300.jpg"],"manuals":[],"options":[],"listPrice":"","quoteOnly":false,"storeLink":"","manualUrls":[],"contentText":"","keyFeatures":[],"availability":"In Stock","optionPrices":{},"catalogNumber":"","performanceData":"","storageStability":""}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('2', 'custom-1757609198384', 'custom-1757609198384', NULL, '/images/products/1-BSY3323_2__Fast_SYBR_Green_qPCR_Master_Mix-300x300.jpg', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '', 'In Stock', '', NULL, TRUE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', NULL, ARRAY[], ARRAY[], ARRAY['/images/products/1-BSY3323_2__Fast_SYBR_Green_qPCR_Master_Mix-300x300.jpg'], 'https://store.bioarktech.com/cart', '', FALSE, '{"id":"custom-1757609198384"}'::jsonb, NULL, '{"images":["/images/products/1-BSY3323_2__Fast_SYBR_Green_qPCR_Master_Mix-300x300.jpg"],"manuals":[],"options":[],"listPrice":"","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"contentText":"","keyFeatures":[],"availability":"In Stock","optionPrices":{},"catalogNumber":"","performanceData":"","storageStability":""}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('3', 'custom-1757746922797', 'custom-1757746922797', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '', 'In Stock', '', NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', NULL, ARRAY[], ARRAY[], ARRAY[], 'https://store.bioarktech.com/cart', '', FALSE, '{"id":"custom-1757746922797"}'::jsonb, NULL, '{"images":[],"manuals":[],"options":[],"listPrice":"","quoteOnly":false,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"contentText":"","keyFeatures":[],"availability":"In Stock","optionPrices":{},"catalogNumber":"","performanceData":"","storageStability":""}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('4', 'custom-1757747120684', 'custom-1757747120684', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '', 'In Stock', '', NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', NULL, ARRAY[], ARRAY[], ARRAY[], 'https://store.bioarktech.com/cart', '', FALSE, '{"id":"custom-1757747120684"}'::jsonb, NULL, '{"images":[],"manuals":[],"options":[],"listPrice":"","quoteOnly":false,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"contentText":"","keyFeatures":[],"availability":"In Stock","optionPrices":{},"catalogNumber":"","performanceData":"","storageStability":""}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('5', 'custom-1757747406537', 'custom-1757747406537', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '', 'In Stock', '', NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', NULL, ARRAY[], ARRAY[], ARRAY[], 'https://store.bioarktech.com/cart', '', FALSE, '{"id":"custom-1757747406537"}'::jsonb, NULL, '{"images":[],"manuals":[],"options":[],"listPrice":"","quoteOnly":false,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"contentText":"","keyFeatures":[],"availability":"In Stock","optionPrices":{},"catalogNumber":"","performanceData":"","storageStability":""}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('6', 'custom-1757747796374', 'custom-1757747796374', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '', 'In Stock', '', NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', NULL, ARRAY[], ARRAY[], ARRAY[], 'https://store.bioarktech.com/cart', '', FALSE, '{"id":"custom-1757747796374"}'::jsonb, NULL, '{"images":[],"manuals":[],"options":[],"listPrice":"","quoteOnly":false,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"contentText":"","keyFeatures":[],"availability":"In Stock","optionPrices":{},"catalogNumber":"","performanceData":"","storageStability":""}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('7', 'custom-1757748063327', 'custom-1757748063327', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '', 'In Stock', '$75.00', NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', NULL, ARRAY[], ARRAY[], ARRAY[], 'https://store.bioarktech.com/cart', '', FALSE, '{"id":"custom-1757748063327"}'::jsonb, NULL, '{"images":[],"manuals":[],"options":[],"listPrice":"$75.00","quoteOnly":false,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"contentText":"","keyFeatures":[],"availability":"In Stock","optionPrices":{},"catalogNumber":"","performanceData":"","storageStability":""}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('8', 'custom-1762801437711', 'custom-1762801437711', NULL, NULL, NULL, NULL, '3', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"custom-1762801437711"}'::jsonb, NULL, NULL, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('9', 'custom-1762801582044', 'custom-1762801582044', NULL, NULL, NULL, NULL, '2', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"custom-1762801582044"}'::jsonb, NULL, NULL, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('10', 'custom-1762801601793', 'custom-1762801601793', NULL, NULL, NULL, NULL, '2', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"custom-1762801601793"}'::jsonb, NULL, NULL, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('11', 'custom-1762801947809', 'custom-1762801947809', NULL, NULL, NULL, NULL, '3', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"custom-1762801947809"}'::jsonb, NULL, NULL, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('12', 'custom-1762803603192', 'custom-1762803603192', NULL, NULL, NULL, NULL, 'zyy', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"custom-1762803603192"}'::jsonb, NULL, NULL, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('13', 'custom-1764990947079', 'custom-1764990947079', NULL, NULL, NULL, NULL, 'DNA', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"custom-1764990947079"}'::jsonb, NULL, NULL, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('14', 'fp-badm3362', 'fp-badm3362', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, TRUE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-badm3362"}'::jsonb, NULL, '{"isFeatured":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('15', 'fp-badm3363', 'fp-badm3363', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, TRUE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-badm3363"}'::jsonb, NULL, '{"isFeatured":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('16', 'fp-badm3364', 'fp-badm3364', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-badm3364"}'::jsonb, NULL, '{"isFeatured":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('17', 'fp-bal100468', 'fp-bal100468', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, TRUE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-bal100468"}'::jsonb, NULL, '{"isFeatured":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('18', 'fp-bapm2083', 'fp-bapm2083', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, TRUE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-bapm2083"}'::jsonb, NULL, '{"isFeatured":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('19', 'fp-bsy3320', 'fp-bsy3320', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-bsy3320"}'::jsonb, NULL, '{"isFeatured":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('20', 'fp-bsy3323', 'fp-bsy3323', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-bsy3323"}'::jsonb, NULL, '{"isFeatured":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('21', 'gep-05', 'KnockIn Kit at Safe Harbor Sites', 'Precise integration to drive robust gene overexpression at safe-harbor or locus-specific sites.', '/content-api/uploads/originals/fc52e6f9-7ac7-4885-9af4-a371e8b37a37.png', '/products/overexpression-targeted-knock-in', 'genome-editing', 'DNA', 'quote', 0, NULL, NULL, 'GEX-003', 'In Stock', '', '$1199+syn.', TRUE, FALSE, FALSE, TRUE, ARRAY['High-purity components for robust genome editing', 'Complete systems for high-titer virus production', 'Scalable solutions for manufacturing', 'Custom-designed for targeted gene editing'], ARRAY['Standard Kit', 'Pro Kit'], '{}'::jsonb, 'Store components at specified temperatures. See manual for details.', 'Consistently high efficiency and low off-target effects reported in publications.', '', ARRAY['Protocol Guide (PDF)', 'Troubleshooting (PDF)'], ARRAY[], ARRAY['/content-api/uploads/originals/fc52e6f9-7ac7-4885-9af4-a371e8b37a37.png', '/content-api/uploads/originals/10dab363-fd33-419a-9002-6be439265a5d.jpg', '/content-api/uploads/originals/85dd272f-4a6c-40fa-b9ff-b59b48e972ab.jpg'], 'https://store.bioarktech.com/cart', '# Safe Harbor Site Gene Integration

This technique enables the precise integration of target genes or regulatory cassettes into safe harbor sites—genomic regions where foreign DNA can be inserted without disrupting essential endogenous gene functions or causing adverse cellular effects. These sites are widely used in genome engineering for stable gene insertion, ensuring long-term and predictable transgene expression.

Commonly used safe harbor sites include human AAVS1 and CCR5, as well as the mouse ROSA26 locus. Our standard kit utilizes the AAVS1 site as the default insertion locus. For alternative loci or custom services, please contact us at support@bioarktech.com.

## Technical Background

CRISPR-Cas9-mediated targeted knock-in at safe harbor sites involves:

- **Cas9**: An endonuclease that creates a double-strand break (DSB) at the target site.
- **Guide RNA (gRNA)**: Directs Cas9 to the specific safe harbor locus, such as AAVS1 or the mouse ROSA26 locus.
- **Donor DNA template**: A construct containing the desired transgene flanked by homology arms complementary to sequences adjacent to the AAVS1 site, facilitating targeted insertion via homology-directed repair (HDR).

## Key Features of Our Products

### Streamlined CRISPR and Donor Vectors
Designed for efficient target gene integration, outperforming commercially available alternatives.

### Targeted vs. Random Integration
Many conventional approaches rely on non-targeting lentiviruses, leading to random gene integration, which can pose safety risks and unpredictable outcomes, particularly in gene therapy and clinical research.

Our vector and virus kits enable precise, targeted integration at safe harbor sites, significantly reducing these risks.

### User-Friendly Plasmid Kits for Broad Accessibility
Unlike many market solutions that require electroporation—necessitating specialized equipment and techniques—our plasmid-based kits are optimized for ease of use, making them ideal for adherent cancer cell lines.

## Product Catalog

10 entries per page  
Search:  
Edit

| Major Vector | Donor Vector | Scramble Control Vector |
|--------------|--------------|-------------------------|
| **Class** | **Product Name** | **SKU** | **Information** | **Donor Name** | **SKU** | **Information** | **Scramble Name** | **SKU** | **Information** |
| Non-Viral CDS-P011k | CRISPR KN AIO Kit-Gene AAVS1, Vector type | COT-FXD00A-AAVS1gk | The CRISPR tool specifically designed to target and cut human AAVS1 safe harbor site. | AAVS1 Dnr Std Kit | CDS-FX00PA-XXXXXXk | Insert Customer Gene into human AAVS1 site, please specify your genes by clicking the button | GFP Donor Control AAVS1 Dnr Std Ctrl Kit, vector type | CDS-FX0GPA-000000k | Insert GFP into human AAVS1 site as control |
| Non-Viral CDS-P011k | CRISPR KN AIO Kit-Gene ROSA26, Vector type | COT-FXD00A-ROSA26gk | The CRISPR tool specifically designed to target and cut mouse ROSA26 safe harbor site. | Dnr Std Kit-ROSA26 Site | TBD | Insert Customer Gene into mouse ROSA26 site, please specify your custom gene by clicking the button | GFP Donor Control Dnr Std Kit-ROSA26 Site, vector type | TBD | Insert GFP into mouse ROSA26 site as control |

Showing 1 to 3 of 3 entries

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.
', FALSE, '{"id":"gep-05"}'::jsonb, '{"link":"/products/overexpression-targeted-knock-in","name":"KnockIn Kit at Safe Harbor Sites","order":0,"__type":"quote","category":"genome-editing","description":"Precise integration to drive robust gene overexpression at safe-harbor or locus-specific sites."}'::jsonb, '{"images":["/content-api/uploads/originals/fc52e6f9-7ac7-4885-9af4-a371e8b37a37.png","/content-api/uploads/originals/10dab363-fd33-419a-9002-6be439265a5d.jpg","/content-api/uploads/originals/85dd272f-4a6c-40fa-b9ff-b59b48e972ab.jpg"],"manuals":["Protocol Guide (PDF)","Troubleshooting (PDF)"],"options":["Standard Kit","Pro Kit"],"listPrice":"","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","isFeatured":false,"manualUrls":[],"priceRange":"$1199+syn.","contentText":"# Safe Harbor Site Gene Integration\n\nThis technique enables the precise integration of target genes or regulatory cassettes into safe harbor sites—genomic regions where foreign DNA can be inserted without disrupting essential endogenous gene functions or causing adverse cellular effects. These sites are widely used in genome engineering for stable gene insertion, ensuring long-term and predictable transgene expression.\n\nCommonly used safe harbor sites include human AAVS1 and CCR5, as well as the mouse ROSA26 locus. Our standard kit utilizes the AAVS1 site as the default insertion locus. For alternative loci or custom services, please contact us at support@bioarktech.com.\n\n## Technical Background\n\nCRISPR-Cas9-mediated targeted knock-in at safe harbor sites involves:\n\n- **Cas9**: An endonuclease that creates a double-strand break (DSB) at the target site.\n- **Guide RNA (gRNA)**: Directs Cas9 to the specific safe harbor locus, such as AAVS1 or the mouse ROSA26 locus.\n- **Donor DNA template**: A construct containing the desired transgene flanked by homology arms complementary to sequences adjacent to the AAVS1 site, facilitating targeted insertion via homology-directed repair (HDR).\n\n## Key Features of Our Products\n\n### Streamlined CRISPR and Donor Vectors\nDesigned for efficient target gene integration, outperforming commercially available alternatives.\n\n### Targeted vs. Random Integration\nMany conventional approaches rely on non-targeting lentiviruses, leading to random gene integration, which can pose safety risks and unpredictable outcomes, particularly in gene therapy and clinical research.\n\nOur vector and virus kits enable precise, targeted integration at safe harbor sites, significantly reducing these risks.\n\n### User-Friendly Plasmid Kits for Broad Accessibility\nUnlike many market solutions that require electroporation—necessitating specialized equipment and techniques—our plasmid-based kits are optimized for ease of use, making them ideal for adherent cancer cell lines.\n\n## Product Catalog\n\n10 entries per page  \nSearch:  \nEdit\n\n| Major Vector | Donor Vector | Scramble Control Vector |\n|--------------|--------------|-------------------------|\n| **Class** | **Product Name** | **SKU** | **Information** | **Donor Name** | **SKU** | **Information** | **Scramble Name** | **SKU** | **Information** |\n| Non-Viral CDS-P011k | CRISPR KN AIO Kit-Gene AAVS1, Vector type | COT-FXD00A-AAVS1gk | The CRISPR tool specifically designed to target and cut human AAVS1 safe harbor site. | AAVS1 Dnr Std Kit | CDS-FX00PA-XXXXXXk | Insert Customer Gene into human AAVS1 site, please specify your genes by clicking the button | GFP Donor Control AAVS1 Dnr Std Ctrl Kit, vector type | CDS-FX0GPA-000000k | Insert GFP into human AAVS1 site as control |\n| Non-Viral CDS-P011k | CRISPR KN AIO Kit-Gene ROSA26, Vector type | COT-FXD00A-ROSA26gk | The CRISPR tool specifically designed to target and cut mouse ROSA26 safe harbor site. | Dnr Std Kit-ROSA26 Site | TBD | Insert Customer Gene into mouse ROSA26 site, please specify your custom gene by clicking the button | GFP Donor Control Dnr Std Kit-ROSA26 Site, vector type | TBD | Insert GFP into mouse ROSA26 site as control |\n\nShowing 1 to 3 of 3 entries\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.\n","keyFeatures":["High-purity components for robust genome editing","Complete systems for high-titer virus production","Scalable solutions for manufacturing","Custom-designed for targeted gene editing"],"availability":"In Stock","optionPrices":{},"catalogNumber":"GEX-003","showInFeatured":false,"dataDescription":"","performanceData":"Consistently high efficiency and low off-target effects reported in publications.","storageStability":"Store components at specified temperatures. See manual for details.","showInGeneEditing":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('22', 'vc-01', 'cDNA Vector Stock', 'Ready-to-use cDNA vector stocks for cloning and expression workflows.', '/content-api/uploads/originals/30248855-528e-46b1-9487-e748b7bbe964.png', '/products/cdna-vector-stock', 'vector-clones', 'Stock', 'quote', 0, NULL, NULL, 'VC-001', 'In Stock', 'Contact for Quote', '', TRUE, TRUE, FALSE, FALSE, ARRAY['High-quality backbone', 'Multiple cloning sites', 'Sequence-verified'], ARRAY[], '{}'::jsonb, 'Store at -20°C. See manual for details.', 'Validated for standard cloning workflows.', '', ARRAY['Vector Handbook (PDF)'], ARRAY[], ARRAY['/content-api/uploads/originals/30248855-528e-46b1-9487-e748b7bbe964.png'], '', 'This technique enables the precise integration of target genes or regulatory cassettes into safe harbor sites—genomic regions where foreign DNA can be inserted without disrupting essential endogenous gene functions or causing adverse cellular effects. These sites are widely used in genome engineering for stable gene insertion, ensuring long-term and predictable transgene expression.

Commonly used safe harbor sites include human AAVS1 and CCR5, as well as the mouse ROSA26 locus. Our standard kit utilizes the AAVS1 site as the default insertion locus. For alternative loci or custom services, please contact us at [support@bioarktech.com](mailto:support@bioarktech.com).

---

| Main Plasmid | Features | | | | | | Scramble Plasmid | Order |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **Class** | **Product Name** | **SKU** | **Accessory** | **Promoter** | **Protein Tag** | **Fluorescence Marker** | **Selection Marker** | **Target Gene** | **Control Sample** | **SKU** |
| Viral | OverExp Lenti Kit | EML-CXD0PC-LARGETk | None | PCMV | MycDDK | None | Puro | LargeT | GFP control | EML-CXDGPC-000000k |
| Viral | OverExp Lenti Kit | EML-CXD0BC-LARGETk | None | PCMV | MycDDK | None | BSD | LargeT | GFP control | EML-CXDGBC-000000k |

*Showing 1 to 3 of 3 entries*

---

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.
```', FALSE, '{"id":"vc-01"}'::jsonb, '{"link":"/products/cdna-vector-stock","name":"cDNA Vector Stock","order":1,"__type":"quote","category":"vector-clones","description":"Ready-to-use cDNA vector stocks for cloning and expression workflows."}'::jsonb, '{"order":0,"images":["/content-api/uploads/originals/30248855-528e-46b1-9487-e748b7bbe964.png"],"manuals":["Vector Handbook (PDF)"],"options":[],"listPrice":"Contact for Quote","quoteOnly":true,"storeLink":"","isFeatured":true,"manualUrls":[],"priceRange":"","contentText":"This technique enables the precise integration of target genes or regulatory cassettes into safe harbor sites—genomic regions where foreign DNA can be inserted without disrupting essential endogenous gene functions or causing adverse cellular effects. These sites are widely used in genome engineering for stable gene insertion, ensuring long-term and predictable transgene expression.\n\nCommonly used safe harbor sites include human AAVS1 and CCR5, as well as the mouse ROSA26 locus. Our standard kit utilizes the AAVS1 site as the default insertion locus. For alternative loci or custom services, please contact us at [support@bioarktech.com](mailto:support@bioarktech.com).\n\n---\n\n| Main Plasmid | Features | | | | | | Scramble Plasmid | Order |\n| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |\n| **Class** | **Product Name** | **SKU** | **Accessory** | **Promoter** | **Protein Tag** | **Fluorescence Marker** | **Selection Marker** | **Target Gene** | **Control Sample** | **SKU** |\n| Viral | OverExp Lenti Kit | EML-CXD0PC-LARGETk | None | PCMV | MycDDK | None | Puro | LargeT | GFP control | EML-CXDGPC-000000k |\n| Viral | OverExp Lenti Kit | EML-CXD0BC-LARGETk | None | PCMV | MycDDK | None | BSD | LargeT | GFP control | EML-CXDGBC-000000k |\n\n*Showing 1 to 3 of 3 entries*\n\n---\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.\n```","keyFeatures":["High-quality backbone","Multiple cloning sites","Sequence-verified"],"availability":"In Stock","optionPrices":{},"catalogNumber":"VC-001","showInFeatured":false,"dataDescription":"","performanceData":"Validated for standard cloning workflows.","storageStability":"Store at -20°C. See manual for details.","showInGeneEditing":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('23', 'vc-02', 'Template Vectors Stock', 'Templates for building functional vector kits with modular components.', '/placeholder.svg', '/products/functional-vectors-kits-template', 'vector-clones', 'Stock', 'quote', 0, NULL, NULL, 'VC-002', 'In Stock', 'Contact for Quote', '', TRUE, FALSE, FALSE, FALSE, ARRAY['Modular design', 'Customizable elements', 'Comprehensive documentation'], ARRAY[], '{}'::jsonb, 'Store at -20°C. See manual for details.', 'Suitable for rapid kit assembly and iteration.', '', ARRAY['Template Guide (PDF)'], ARRAY[], ARRAY['/placeholder.svg'], '', '# BioArk Technologies

BioArk Technologies offers an extensive inventory of vectors, optimized for automated cloning design and construction. Our pre-assembled templates can be quickly adapted and customized into different kits, tailored for various applications. You can utilize these established systems for your project or design your own system based on your specific preferences.

Below is a list of our current established function kits. Simply click the SKU number to add your preferred gene information or just select the control or scramble vectors.

---

| Major Vector | Features | | | | | Scramble Vector |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **Class** | **Product Name** | **SKU** | **Accessory Vector** | **Promoter** | **Tag** | **Fluorescence Marker** | **Selection Marker** | **Control Sample** | **SKU** |
| Non-Viral All-in-One | CRISPRa AIO Kit | CAT-FXD00A-XXXXXXk | None | EF1core | MycDDK | None | None | Scramble Control | CAT-FXD00A-000000k |
| Viral All-in-one | CRISPRa AIO Kit | CAM-FXD0PC-XXXXXXk | None | EF1core | MycDDK | None | Puro | Scramble Control | CAM-FXD0PC-000000k |

*Showing 1 to 3 of 3 entries*

---

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.
```', FALSE, '{"id":"vc-02"}'::jsonb, '{"link":"/products/functional-vectors-kits-template","name":"Template Vectors Stock","order":0,"__type":"quote","category":"vector-clones","description":"Templates for building functional vector kits with modular components."}'::jsonb, '{"images":["/placeholder.svg"],"manuals":["Template Guide (PDF)"],"options":[],"listPrice":"Contact for Quote","quoteOnly":true,"storeLink":"","isFeatured":false,"manualUrls":[],"priceRange":"","contentText":"# BioArk Technologies\n\nBioArk Technologies offers an extensive inventory of vectors, optimized for automated cloning design and construction. Our pre-assembled templates can be quickly adapted and customized into different kits, tailored for various applications. You can utilize these established systems for your project or design your own system based on your specific preferences.\n\nBelow is a list of our current established function kits. Simply click the SKU number to add your preferred gene information or just select the control or scramble vectors.\n\n---\n\n| Major Vector | Features | | | | | Scramble Vector |\n| :--- | :--- | :--- | :--- | :--- | :--- | :--- |\n| **Class** | **Product Name** | **SKU** | **Accessory Vector** | **Promoter** | **Tag** | **Fluorescence Marker** | **Selection Marker** | **Control Sample** | **SKU** |\n| Non-Viral All-in-One | CRISPRa AIO Kit | CAT-FXD00A-XXXXXXk | None | EF1core | MycDDK | None | None | Scramble Control | CAT-FXD00A-000000k |\n| Viral All-in-one | CRISPRa AIO Kit | CAM-FXD0PC-XXXXXXk | None | EF1core | MycDDK | None | Puro | Scramble Control | CAM-FXD0PC-000000k |\n\n*Showing 1 to 3 of 3 entries*\n\n---\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.\n```","keyFeatures":["Modular design","Customizable elements","Comprehensive documentation"],"availability":"In Stock","optionPrices":{},"catalogNumber":"VC-002","showInFeatured":false,"dataDescription":"","performanceData":"Suitable for rapid kit assembly and iteration.","storageStability":"Store at -20°C. See manual for details.","showInGeneEditing":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('24', 'fp-bal100688', 'fp-bal100688', NULL, NULL, NULL, NULL, NULL, NULL, 1, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-bal100688"}'::jsonb, NULL, '{"order":1,"isFeatured":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('25', 'gep-01', 'Gene Tagging Kit', 'Precision services for endogenous gene tagging and reporter knock-in.', '/content-api/uploads/originals/3b93f03a-4932-4a55-a0be-0acfc63a9b42.png', '/products/gene-knock-in', 'genome-editing', 'DNA', 'quote', 1, NULL, NULL, 'GEX-004', 'In Stock', '$640.37', '$1199+syn.', TRUE, FALSE, FALSE, TRUE, ARRAY['High-purity components for robust genome editing', 'Complete systems for high-titer virus production', 'Scalable solutions for manufacturing', 'Custom-designed for targeted gene editing'], ARRAY['Standard Kit', 'Pro Kit'], '{}'::jsonb, 'Store components at specified temperatures. See manual for details.', 'Consistently high efficiency and low off-target effects reported in publications.', '', ARRAY['Protocol Guide (PDF)', 'Troubleshooting (PDF)'], ARRAY[], ARRAY['/content-api/uploads/originals/3b93f03a-4932-4a55-a0be-0acfc63a9b42.png'], 'https://store.bioarktech.com/cart', 'This technique provides versatile options for attaching selected tags to the 3′ or 5′ ends of customer-specified target genes, enabling precise tracking and functional analysis. Gene knock-in tagging can be applied across a broad range of research areas, including investigating protein localization, studying protein-protein interactions, analyzing gene function and regulation, creating transgenic models, and facilitating drug discovery efforts.

## Technical Background

The CRISPR-Cas9 system is the core technology behind gene knock-in tagging. It utilizes a guide RNA (gRNA) to direct the Cas9 endonuclease to a specific genomic site, where it generates a double-strand break (DSB). This break is then repaired by either non-homologous end joining (NHEJ) or homology-directed repair (HDR). For knock-in tagging, HDR is the preferred method, where a donor template containing the desired tag, flanked by homology arms, facilitates the precise insertion of the tag at the target locus.

## Key Components

- **Cas9 protein**: Creates a DSB at the target site.
- **Guide RNA (gRNA)**: Directs Cas9 to the desired genomic locus.
- **Donor template**: Contains the tag (e.g., GFP, HA tag) along with homology arms to facilitate HDR-mediated knock-in.

## Features of Our Products

- **AI-Assisted Design**: Our CRISPR and donor vectors are AI-assisted, designed to streamline and optimize the process for efficient target gene integration.
- **User-Friendly Techniques**: Our plasmid kits utilize lab-friendly methods that avoid the need for electroporation, making them easy to use in most labs. They are particularly well-suited for adherent cancer cell lines.

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.', FALSE, '{"id":"gep-01"}'::jsonb, '{"link":"/products/gene-knock-in","name":"Gene Tagging Kit","order":1,"__type":"quote","category":"genome-editing","description":"Precision services for endogenous gene tagging and reporter knock-in."}'::jsonb, '{"images":["/content-api/uploads/originals/3b93f03a-4932-4a55-a0be-0acfc63a9b42.png"],"manuals":["Protocol Guide (PDF)","Troubleshooting (PDF)"],"options":["Standard Kit","Pro Kit"],"listPrice":"$640.37","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"priceRange":"$1199+syn.","contentText":"This technique provides versatile options for attaching selected tags to the 3′ or 5′ ends of customer-specified target genes, enabling precise tracking and functional analysis. Gene knock-in tagging can be applied across a broad range of research areas, including investigating protein localization, studying protein-protein interactions, analyzing gene function and regulation, creating transgenic models, and facilitating drug discovery efforts.\n\n## Technical Background\n\nThe CRISPR-Cas9 system is the core technology behind gene knock-in tagging. It utilizes a guide RNA (gRNA) to direct the Cas9 endonuclease to a specific genomic site, where it generates a double-strand break (DSB). This break is then repaired by either non-homologous end joining (NHEJ) or homology-directed repair (HDR). For knock-in tagging, HDR is the preferred method, where a donor template containing the desired tag, flanked by homology arms, facilitates the precise insertion of the tag at the target locus.\n\n## Key Components\n\n- **Cas9 protein**: Creates a DSB at the target site.\n- **Guide RNA (gRNA)**: Directs Cas9 to the desired genomic locus.\n- **Donor template**: Contains the tag (e.g., GFP, HA tag) along with homology arms to facilitate HDR-mediated knock-in.\n\n## Features of Our Products\n\n- **AI-Assisted Design**: Our CRISPR and donor vectors are AI-assisted, designed to streamline and optimize the process for efficient target gene integration.\n- **User-Friendly Techniques**: Our plasmid kits utilize lab-friendly methods that avoid the need for electroporation, making them easy to use in most labs. They are particularly well-suited for adherent cancer cell lines.\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.","keyFeatures":["High-purity components for robust genome editing","Complete systems for high-titer virus production","Scalable solutions for manufacturing","Custom-designed for targeted gene editing"],"availability":"In Stock","optionPrices":{},"catalogNumber":"GEX-004","showInFeatured":false,"dataDescription":"","performanceData":"Consistently high efficiency and low off-target effects reported in publications.","storageStability":"Store components at specified temperatures. See manual for details.","showInGeneEditing":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('26', 'fp-bapm2086', 'fp-bapm2086', NULL, NULL, NULL, NULL, NULL, NULL, 2, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, TRUE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-bapm2086"}'::jsonb, NULL, '{"order":2,"isFeatured":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('27', 'gep-03', 'Gene Deletion Kit', 'Expertly remove large genomic regions to study gene function.', '/content-api/uploads/originals/d650e3bb-1045-4bef-abcd-d9baf2e92493.png', '/products/gene-deletion', 'genome-editing', 'DNA', 'quote', 2, NULL, NULL, 'GEX-002', 'In Stock', '$320.67', '$1499', TRUE, FALSE, FALSE, TRUE, ARRAY['High-purity components for robust genome editing', 'Complete systems for high-titer virus production', 'Scalable solutions for manufacturing', 'Custom-designed for targeted gene editing'], ARRAY['Standard Kit', 'Pro Kit'], '{}'::jsonb, 'Store components at specified temperatures. See manual for details.', 'Consistently high efficiency and low off-target effects reported in publications.', '', ARRAY['Protocol Guide (PDF)', 'Troubleshooting (PDF)'], ARRAY[], ARRAY['/content-api/uploads/originals/d650e3bb-1045-4bef-abcd-d9baf2e92493.png'], 'https://store.bioarktech.com/cart', 'CRISPR Genome Knockout Deletion provides an efficient method for deleting genomic fragments of various sizes, ranging from short deletions to large deletions exceeding 10 kb. It is a valuable tool for studying the functions of non-coding regions of the genome, creating disease models such as Huntington’s disease, exploring gene cluster complexities, investigating chromatin architecture, and examining the role of pathogenic copy number variations (CNVs).

 
Technical Background
Key Components:

Cas9 Protein: A nuclease that creates double-strand breaks (DSBs) at specified genomic locations, guided by a complementary RNA sequence.
Guide RNA (gRNA): A synthetic RNA molecule designed to bind to a specific target sequence in the genome, directing the Cas9 protein to the desired site.
DNA Repair Mechanisms: After the DSB is introduced by Cas9, the cell’s natural repair mechanisms take over. The primary repair pathways involved are:
Non-Homologous End Joining (NHEJ): The predominant pathway for gene knockout, NHEJ can lead to insertions or deletions (indels) at the break site, causing frameshifts or premature stop codons that result in gene knockout.
Homology-Directed Repair (HDR): Although not commonly used for knockout deletions, HDR can be applied for precise gene editing when a donor template is provided.
 
Features of Our Products
Flexible Cloning Options: We offer three different cloning methods for the CRISPR deletion kit:
Cas9 vector with a separate gRNA vector.
Two distinct Cas9 + gRNA All-in-one vectors. Each vector carries one gRNA.
A specialized vector designed for the simultaneous delivery of two gRNAs, allowing for the efficient removal of target genomic fragments.
User-Friendly Techniques: Our plasmid kits are designed to be lab-friendly, eliminating the need for electroporation and making them easy to use in most lab settings. These kits are particularly well-suited for adherent cancer cell lines.

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.', FALSE, '{"id":"gep-03"}'::jsonb, '{"link":"/products/gene-deletion","name":"Gene Deletion Kit","order":2,"__type":"quote","category":"genome-editing","description":"Expertly remove large genomic regions to study gene function."}'::jsonb, '{"images":["/content-api/uploads/originals/d650e3bb-1045-4bef-abcd-d9baf2e92493.png"],"manuals":["Protocol Guide (PDF)","Troubleshooting (PDF)"],"options":["Standard Kit","Pro Kit"],"listPrice":"$320.67","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"priceRange":"$1499","contentText":"CRISPR Genome Knockout Deletion provides an efficient method for deleting genomic fragments of various sizes, ranging from short deletions to large deletions exceeding 10 kb. It is a valuable tool for studying the functions of non-coding regions of the genome, creating disease models such as Huntington’s disease, exploring gene cluster complexities, investigating chromatin architecture, and examining the role of pathogenic copy number variations (CNVs).\n\n \nTechnical Background\nKey Components:\n\nCas9 Protein: A nuclease that creates double-strand breaks (DSBs) at specified genomic locations, guided by a complementary RNA sequence.\nGuide RNA (gRNA): A synthetic RNA molecule designed to bind to a specific target sequence in the genome, directing the Cas9 protein to the desired site.\nDNA Repair Mechanisms: After the DSB is introduced by Cas9, the cell’s natural repair mechanisms take over. The primary repair pathways involved are:\nNon-Homologous End Joining (NHEJ): The predominant pathway for gene knockout, NHEJ can lead to insertions or deletions (indels) at the break site, causing frameshifts or premature stop codons that result in gene knockout.\nHomology-Directed Repair (HDR): Although not commonly used for knockout deletions, HDR can be applied for precise gene editing when a donor template is provided.\n \nFeatures of Our Products\nFlexible Cloning Options: We offer three different cloning methods for the CRISPR deletion kit:\nCas9 vector with a separate gRNA vector.\nTwo distinct Cas9 + gRNA All-in-one vectors. Each vector carries one gRNA.\nA specialized vector designed for the simultaneous delivery of two gRNAs, allowing for the efficient removal of target genomic fragments.\nUser-Friendly Techniques: Our plasmid kits are designed to be lab-friendly, eliminating the need for electroporation and making them easy to use in most lab settings. These kits are particularly well-suited for adherent cancer cell lines.\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.","keyFeatures":["High-purity components for robust genome editing","Complete systems for high-titer virus production","Scalable solutions for manufacturing","Custom-designed for targeted gene editing"],"availability":"In Stock","optionPrices":{},"catalogNumber":"GEX-002","showInFeatured":false,"dataDescription":"","performanceData":"Consistently high efficiency and low off-target effects reported in publications.","storageStability":"Store components at specified temperatures. See manual for details.","showInGeneEditing":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('28', 'fp-bal100668', 'fp-bal100668', NULL, NULL, NULL, NULL, NULL, NULL, 3, NULL, NULL, NULL, NULL, NULL, NULL, FALSE, TRUE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, NULL, NULL, NULL, ARRAY[], ARRAY[], ARRAY[], NULL, NULL, FALSE, '{"id":"fp-bal100668"}'::jsonb, NULL, '{"order":3,"isFeatured":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('29', 'gep-04', 'CRISPR Knockdown Kit', 'Modulate gene expression with our reliable RNA interference services.', '/content-api/uploads/originals/aba9a3b2-8f86-40bb-8668-30a1686f4b13.png', '/products/crispr-knock-down', 'genome-editing', 'RNA', 'quote', 3, NULL, NULL, 'GEX-007', 'In Stock', '$384.90', '$799', TRUE, FALSE, TRUE, FALSE, ARRAY['High-purity components for robust genome editing', 'Complete systems for high-titer virus production', 'Scalable solutions for manufacturing', 'Custom-designed for targeted gene editing'], ARRAY['Standard Kit', 'Pro Kit'], '{}'::jsonb, 'Store components at specified temperatures. See manual for details.', 'Consistently high efficiency and low off-target effects reported in publications.', '', ARRAY['Protocol Guide (PDF)', 'Troubleshooting (PDF)'], ARRAY[], ARRAY['/content-api/uploads/originals/aba9a3b2-8f86-40bb-8668-30a1686f4b13.png'], 'https://store.bioarktech.com/cart', '# CRISPR RNA Knockdown (KD) Technique

This technique offers a more specific and efficient alternative to traditional RNAi methods for knocking down RNA expression levels. CRISPR RNA knockdown using Cas13 provides a powerful and precise approach to regulate gene expression at the RNA level. Its ability to selectively degrade mRNA transcripts makes it a versatile tool for studying gene function and developing therapeutic strategies across diverse fields, including basic research, applied biotechnology, and medicine.

CRISPR RNA knockdown (KD) is particularly useful for studying gene roles by reducing RNA transcript levels. It can be applied in:
- Disease models
- Therapeutic development
- RNA regulatory mechanisms
- Customized RNA therapies
- Antiviral applications
- High-throughput genetic screening

## Technical Background

### Key Components:

- **RfxCas13d (CasRx) Protein**: A member of the CRISPR family that specifically targets RNA rather than DNA. RfxCas13d is derived from the bacterium *Rhodococcus fascians*.
- **Guide RNA (gRNA)**: A synthetic RNA molecule designed to bind to the target mRNA. It contains a sequence complementary to the target RNA, guiding Cas13 to the specific mRNA for cleavage.

## Features of Our Products

- **Reduced Off-Target Effects**: Compared to traditional RNA interference (RNAi), this method significantly minimizes off-target activity in cultured cells, offering greater specificity.
- **Customizable Kits**: We provide two distinct kits—vector kits designed for use with cancer cell lines and virus kits tailored for hard-to-transfect cells.

---

## Product Catalog

10 entries per page  
Search:  
Edit

| Major Vector | Scramble Control Vector |  |  |  |
| :--- | :--- | :--- | :--- | :--- |
| **Class** | **Product Name** | **SKU** | **Information** | **Scramble Name** | **SKU** | **Information** |
| Non-Viral All-In-one | COT-P031k | CRISPR KN AIO Kit | COT-FXD0PA-XXXXXXk | The non-viral CRISPR kit includes three AI-designed gRNA sites tailored to target the customer-specified genes. Please click button to design the target genes. | Scramble Control CRISPR KN AIO Ctrl Kit, Vector type | COT-FXD0PA-000000k | The scramble sequence are used as non-specific cutting control |
| Viral All-in-one | COM-P032k | CRISPR KN Lenti-AIO Kit | COM-FXD0PA-XXXXXXl | The CRISPR lentivirus kit packages three AI-designed gRNA sites into a single mixture tube for precise targeting and cutting of customer-specified genes. Please click button to design the target genes. | Scramble Control CRISPR KN Lenti-AIO Ctrl Kit, lentivirus type | COM-FXD0PA-000000l | The scramble sequence are used as non-specific cutting control |

Showing 1 to 3 of 3 entries

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.
', FALSE, '{"id":"gep-04"}'::jsonb, '{"link":"/products/crispr-knock-down","name":"CRISPR Knockdown Kit","order":3,"__type":"quote","category":"genome-editing","description":"Modulate gene expression with our reliable RNA interference services."}'::jsonb, '{"images":["/content-api/uploads/originals/aba9a3b2-8f86-40bb-8668-30a1686f4b13.png"],"manuals":["Protocol Guide (PDF)","Troubleshooting (PDF)"],"options":["Standard Kit","Pro Kit"],"listPrice":"$384.90","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"priceRange":"$799","contentText":"# CRISPR RNA Knockdown (KD) Technique\n\nThis technique offers a more specific and efficient alternative to traditional RNAi methods for knocking down RNA expression levels. CRISPR RNA knockdown using Cas13 provides a powerful and precise approach to regulate gene expression at the RNA level. Its ability to selectively degrade mRNA transcripts makes it a versatile tool for studying gene function and developing therapeutic strategies across diverse fields, including basic research, applied biotechnology, and medicine.\n\nCRISPR RNA knockdown (KD) is particularly useful for studying gene roles by reducing RNA transcript levels. It can be applied in:\n- Disease models\n- Therapeutic development\n- RNA regulatory mechanisms\n- Customized RNA therapies\n- Antiviral applications\n- High-throughput genetic screening\n\n## Technical Background\n\n### Key Components:\n\n- **RfxCas13d (CasRx) Protein**: A member of the CRISPR family that specifically targets RNA rather than DNA. RfxCas13d is derived from the bacterium *Rhodococcus fascians*.\n- **Guide RNA (gRNA)**: A synthetic RNA molecule designed to bind to the target mRNA. It contains a sequence complementary to the target RNA, guiding Cas13 to the specific mRNA for cleavage.\n\n## Features of Our Products\n\n- **Reduced Off-Target Effects**: Compared to traditional RNA interference (RNAi), this method significantly minimizes off-target activity in cultured cells, offering greater specificity.\n- **Customizable Kits**: We provide two distinct kits—vector kits designed for use with cancer cell lines and virus kits tailored for hard-to-transfect cells.\n\n---\n\n## Product Catalog\n\n10 entries per page  \nSearch:  \nEdit\n\n| Major Vector | Scramble Control Vector |  |  |  |\n| :--- | :--- | :--- | :--- | :--- |\n| **Class** | **Product Name** | **SKU** | **Information** | **Scramble Name** | **SKU** | **Information** |\n| Non-Viral All-In-one | COT-P031k | CRISPR KN AIO Kit | COT-FXD0PA-XXXXXXk | The non-viral CRISPR kit includes three AI-designed gRNA sites tailored to target the customer-specified genes. Please click button to design the target genes. | Scramble Control CRISPR KN AIO Ctrl Kit, Vector type | COT-FXD0PA-000000k | The scramble sequence are used as non-specific cutting control |\n| Viral All-in-one | COM-P032k | CRISPR KN Lenti-AIO Kit | COM-FXD0PA-XXXXXXl | The CRISPR lentivirus kit packages three AI-designed gRNA sites into a single mixture tube for precise targeting and cutting of customer-specified genes. Please click button to design the target genes. | Scramble Control CRISPR KN Lenti-AIO Ctrl Kit, lentivirus type | COM-FXD0PA-000000l | The scramble sequence are used as non-specific cutting control |\n\nShowing 1 to 3 of 3 entries\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.\n","keyFeatures":["High-purity components for robust genome editing","Complete systems for high-titer virus production","Scalable solutions for manufacturing","Custom-designed for targeted gene editing"],"availability":"In Stock","optionPrices":{},"catalogNumber":"GEX-007","showInFeatured":true,"dataDescription":"","performanceData":"Consistently high efficiency and low off-target effects reported in publications.","storageStability":"Store components at specified temperatures. See manual for details.","showInGeneEditing":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('30', 'gep-02', 'CRISPR KnockOut Kit', 'Generate complete loss-of-function models using CRISPR-Cas9 technology.', '/content-api/uploads/originals/ddbc6621-4c4f-470c-8730-6ccdcd6c1c1a.png', '/products/gene-knock-out', 'genome-editing', 'DNA', 'quote', 4, NULL, NULL, 'GEX-001', 'In Stock', '$546.36', '$799', TRUE, FALSE, FALSE, TRUE, ARRAY['High-purity components for robust genome editing', 'Complete systems for high-titer virus production', 'Scalable solutions for manufacturing', 'Custom-designed for targeted gene editing'], ARRAY['Standard Kit', 'Pro Kit'], '{}'::jsonb, 'Store components at specified temperatures. See manual for details.', 'Consistently high efficiency and low off-target effects reported in publications.', '', ARRAY['Protocol Guide (PDF)', 'Troubleshooting (PDF)'], ARRAY[], ARRAY['/content-api/uploads/originals/ddbc6621-4c4f-470c-8730-6ccdcd6c1c1a.png', '/content-api/uploads/originals/e517607f-dde5-4e77-96ba-ad123c4b3ea8.png'], 'https://store.bioarktech.com/cart', '# CRISPR Knockout (KO) Technique

CRISPR knockout (KO) is a revolutionary gene-editing technique that allows researchers to disrupt or "knock out" specific genes within an organism’s genome. The CRISPR-Cas9 system is the most widely used tool for this purpose, harnessing a natural bacterial defense mechanism against viral infections. Our technique provides a rapid and efficient approach to disrupt gene expression for both research and therapeutic applications.

## Technical Background

### Description:

- **spCas9 Protein**: An endonuclease that induces double-strand breaks (DSBs) in DNA at specific genomic loci.
- **Guide RNA (gRNA)**: A short RNA sequence that guides the Cas9 protein to the target gene through complementary base pairing.
- **Repair Pathways**: Following the creation of a DSB, the cell’s repair machinery is activated. The primary repair pathways are:
  - **Non-Homologous End Joining (NHEJ)**: This repair mechanism often results in insertions or deletions (indels) at the break site, leading to frameshift mutations that can disrupt gene function.
  - **Homology-Directed Repair (HDR)**: Typically used for precise edits, HDR can also be employed when a donor template is provided. Although HDR is less common for knockout purposes, it can be leveraged to integrate exogenous DNA into the genome, facilitating quick screening for knockout stable cell lines.

By utilizing the NHEJ repair pathway, researchers can efficiently create gene knockouts, resulting in the loss of gene function. On the other hand, using HDR allows for precise integration of exogenous DNA fragments into the genome.

## Features of Our Products

- **Dual Repair Pathways**: Our CRISPR knockout (KN) tool supports both NHEJ and HDR, offering flexibility depending on customer preferences and project requirements.
- **Two Delivery Options**: We provide two versions of our CRISPR KN tool: lentivirus and regular plasmid, allowing customers to choose the most suitable option for their needs.
- **Superior Knockout Efficiency**: Our tools deliver enhanced knockout efficiency, leveraging the latest advancements in CRISPR technology, including optimized gRNA scaffold structures and improved gRNA sequence selection.

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.

---

## Product Catalog

10 entries per page  
Search:  
Edit

| Major Vector | Scramble Control Vector |  |  |  |
| :--- | :--- | :--- | :--- | :--- |
| **Class** | **Product Name** | **SKU** | **Information** | **Scramble Name** | **SKU** | **Information** |
| Non-Viral All-In-one | COT-P031k | CRISPR KN AIO Kit | COT-FXD0PA-XXXXXXk | The non-viral CRISPR kit includes three AI-designed gRNA sites tailored to target the customer-specified genes. Please click button to design the target genes. | Scramble Control CRISPR KN AIO Ctrl Kit, Vector type | COT-FXD0PA-000000k | The scramble sequence are used as non-specific cutting control |
| Viral All-in-one | COM-P032k | CRISPR KN Lenti-AIO Kit | COM-FXD0PA-XXXXXXl | The CRISPR lentivirus kit packages three AI-designed gRNA sites into a single mixture tube for precise targeting and cutting of customer-specified genes. Please click button to design the target genes. | Scramble Control CRISPR KN Lenti-AIO Ctrl Kit, lentivirus type | COM-FXD0PA-000000l | The scramble sequence are used as non-specific cutting control |
', FALSE, '{"id":"gep-02"}'::jsonb, '{"link":"/products/gene-knock-out","name":"CRISPR KnockOut Kit","order":4,"__type":"quote","category":"genome-editing","description":"Generate complete loss-of-function models using CRISPR-Cas9 technology."}'::jsonb, '{"images":["/content-api/uploads/originals/ddbc6621-4c4f-470c-8730-6ccdcd6c1c1a.png","/content-api/uploads/originals/e517607f-dde5-4e77-96ba-ad123c4b3ea8.png"],"manuals":["Protocol Guide (PDF)","Troubleshooting (PDF)"],"options":["Standard Kit","Pro Kit"],"listPrice":"$546.36","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"priceRange":"$799","contentText":"# CRISPR Knockout (KO) Technique\n\nCRISPR knockout (KO) is a revolutionary gene-editing technique that allows researchers to disrupt or \"knock out\" specific genes within an organism’s genome. The CRISPR-Cas9 system is the most widely used tool for this purpose, harnessing a natural bacterial defense mechanism against viral infections. Our technique provides a rapid and efficient approach to disrupt gene expression for both research and therapeutic applications.\n\n## Technical Background\n\n### Description:\n\n- **spCas9 Protein**: An endonuclease that induces double-strand breaks (DSBs) in DNA at specific genomic loci.\n- **Guide RNA (gRNA)**: A short RNA sequence that guides the Cas9 protein to the target gene through complementary base pairing.\n- **Repair Pathways**: Following the creation of a DSB, the cell’s repair machinery is activated. The primary repair pathways are:\n  - **Non-Homologous End Joining (NHEJ)**: This repair mechanism often results in insertions or deletions (indels) at the break site, leading to frameshift mutations that can disrupt gene function.\n  - **Homology-Directed Repair (HDR)**: Typically used for precise edits, HDR can also be employed when a donor template is provided. Although HDR is less common for knockout purposes, it can be leveraged to integrate exogenous DNA into the genome, facilitating quick screening for knockout stable cell lines.\n\nBy utilizing the NHEJ repair pathway, researchers can efficiently create gene knockouts, resulting in the loss of gene function. On the other hand, using HDR allows for precise integration of exogenous DNA fragments into the genome.\n\n## Features of Our Products\n\n- **Dual Repair Pathways**: Our CRISPR knockout (KN) tool supports both NHEJ and HDR, offering flexibility depending on customer preferences and project requirements.\n- **Two Delivery Options**: We provide two versions of our CRISPR KN tool: lentivirus and regular plasmid, allowing customers to choose the most suitable option for their needs.\n- **Superior Knockout Efficiency**: Our tools deliver enhanced knockout efficiency, leveraging the latest advancements in CRISPR technology, including optimized gRNA scaffold structures and improved gRNA sequence selection.\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.\n\n---\n\n## Product Catalog\n\n10 entries per page  \nSearch:  \nEdit\n\n| Major Vector | Scramble Control Vector |  |  |  |\n| :--- | :--- | :--- | :--- | :--- |\n| **Class** | **Product Name** | **SKU** | **Information** | **Scramble Name** | **SKU** | **Information** |\n| Non-Viral All-In-one | COT-P031k | CRISPR KN AIO Kit | COT-FXD0PA-XXXXXXk | The non-viral CRISPR kit includes three AI-designed gRNA sites tailored to target the customer-specified genes. Please click button to design the target genes. | Scramble Control CRISPR KN AIO Ctrl Kit, Vector type | COT-FXD0PA-000000k | The scramble sequence are used as non-specific cutting control |\n| Viral All-in-one | COM-P032k | CRISPR KN Lenti-AIO Kit | COM-FXD0PA-XXXXXXl | The CRISPR lentivirus kit packages three AI-designed gRNA sites into a single mixture tube for precise targeting and cutting of customer-specified genes. Please click button to design the target genes. | Scramble Control CRISPR KN Lenti-AIO Ctrl Kit, lentivirus type | COM-FXD0PA-000000l | The scramble sequence are used as non-specific cutting control |\n","keyFeatures":["High-purity components for robust genome editing","Complete systems for high-titer virus production","Scalable solutions for manufacturing","Custom-designed for targeted gene editing"],"availability":"In Stock","optionPrices":{},"catalogNumber":"GEX-001","showInFeatured":false,"dataDescription":"","performanceData":"Consistently high efficiency and low off-target effects reported in publications.","storageStability":"Store components at specified temperatures. See manual for details.","showInGeneEditing":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('31', 'custom-1759624148236', 'CRISPR Activation Kit', 'Our CRISPR activation (CRISPRa) kits enable precise, reversible upregulation of endogenous genes without altering DNA sequences. Powered by nuclease-deactivated Cas9 (dCas9) fused to potent transcriptional activators, the platform offers a robust solution for functional genomics, pathway analysis, and therapeutic research. Each kit includes three target-specific gRNA vectors (all-in-one or standalone format) and one scramble control.', '/content-api/uploads/originals/aa6a0b48-05c6-47d2-8764-87d73b4c7824.png', '/products/crispr-activation', 'genome-editing', 'DNA', 'quote', 5, '1759624148236', '2025-10-05T00:29:08.236Z', 'GEX-006', 'In Stock', '', '$799', TRUE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', '', ARRAY[], ARRAY[], ARRAY['/content-api/uploads/originals/aa6a0b48-05c6-47d2-8764-87d73b4c7824.png'], 'https://store.bioarktech.com/cart', '
**CRISPR activation (CRISPRa)** is an advanced gene-regulation technology that enables researchers to **upregulate or activate the expression** of target genes **without altering the underlying DNA sequence**.  

Unlike CRISPR knockout, which disrupts gene function, CRISPRa employs a **nuclease-deactivated Cas9 (dCas9)** fused to **transcriptional activators**, allowing **precise control of gene expression**.  

Our system provides a **rapid, efficient, and reversible** approach to enhance gene expression—ideal for **functional genomics**, **pathway analysis**, and **therapeutic research**.

Each kit includes **three target-specific gRNA vectors** (available in **all-in-one** or **standalone** format) and **one scramble control vector**, offering flexibility for both experimental validation and control design.

---

## Technical Background

1. **dCas9 Protein**  
   A catalytically inactive Cas9 variant that binds to specific genomic loci guided by gRNA, without inducing double-strand breaks.  

2. **Guide RNA (gRNA)**  
   A short RNA sequence that directs dCas9 to the promoter or enhancer region of a target gene, enabling site-specific activation.  

3. **Transcriptional Activators**  
   - **VP64, p65, Rta, or VPR fusions**: Potent activator domains that recruit the cell’s transcriptional machinery to drive robust gene expression.  
   - **MS2 or SAM system (optional)**: Enhanced multi-component activation systems that further amplify transcriptional output.  

By precisely positioning **dCas9-activator complexes** near promoter regions, researchers can **turn on endogenous gene expression**, enabling **fine-tuned control** for mechanistic studies or phenotype screening.

---

## Features of Our Products

1. **High Activation Efficiency**  
   Our CRISPRa platform integrates optimized gRNA design and advanced activator domains to achieve **strong and consistent gene upregulation**.

2. **Multiple Delivery Options**  
   Available in both **lentiviral** and **plasmid** formats, allowing **flexible delivery** to a wide range of cell types, including difficult-to-transfect cells.

3. **All-in-One or Standalone Configurations**  
   Choose between **all-in-one** and **standalone** formats to suit your experimental needs:  
   - **All-in-One**: Cas9 activator and gRNA cassettes are integrated into a single vector for streamlined transfection and stable expression.  
   - **Standalone**: Cas9 activator and gRNA are provided on separate plasmids, offering greater modularity and experimental control.

4. **Comprehensive Kit Design**  
   Each kit contains **three gRNA vectors** targeting the gene of interest and **one scramble control**, ensuring reliable results with appropriate experimental controls.
', FALSE, '{"id":"custom-1759624148236","link":"/products/crispr-activation","name":"CRISPR Activation Kit","order":5,"__type":"quote","category":"genome-editing","imageUrl":"","createdAt":1759624148236,"description":"Our CRISPR activation (CRISPRa) kits enable precise, reversible upregulation of endogenous genes without altering DNA sequences. Powered by nuclease-deactivated Cas9 (dCas9) fused to potent transcriptional activators, the platform offers a robust solution for functional genomics, pathway analysis, and therapeutic research. Each kit includes three target-specific gRNA vectors (all-in-one or standalone format) and one scramble control."}'::jsonb, NULL, '{"images":["/content-api/uploads/originals/aa6a0b48-05c6-47d2-8764-87d73b4c7824.png"],"manuals":[],"options":[],"createdAt":1759624148236,"listPrice":"","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"priceRange":"$799","contentText":"\n**CRISPR activation (CRISPRa)** is an advanced gene-regulation technology that enables researchers to **upregulate or activate the expression** of target genes **without altering the underlying DNA sequence**.  \n\nUnlike CRISPR knockout, which disrupts gene function, CRISPRa employs a **nuclease-deactivated Cas9 (dCas9)** fused to **transcriptional activators**, allowing **precise control of gene expression**.  \n\nOur system provides a **rapid, efficient, and reversible** approach to enhance gene expression—ideal for **functional genomics**, **pathway analysis**, and **therapeutic research**.\n\nEach kit includes **three target-specific gRNA vectors** (available in **all-in-one** or **standalone** format) and **one scramble control vector**, offering flexibility for both experimental validation and control design.\n\n---\n\n## Technical Background\n\n1. **dCas9 Protein**  \n   A catalytically inactive Cas9 variant that binds to specific genomic loci guided by gRNA, without inducing double-strand breaks.  \n\n2. **Guide RNA (gRNA)**  \n   A short RNA sequence that directs dCas9 to the promoter or enhancer region of a target gene, enabling site-specific activation.  \n\n3. **Transcriptional Activators**  \n   - **VP64, p65, Rta, or VPR fusions**: Potent activator domains that recruit the cell’s transcriptional machinery to drive robust gene expression.  \n   - **MS2 or SAM system (optional)**: Enhanced multi-component activation systems that further amplify transcriptional output.  \n\nBy precisely positioning **dCas9-activator complexes** near promoter regions, researchers can **turn on endogenous gene expression**, enabling **fine-tuned control** for mechanistic studies or phenotype screening.\n\n---\n\n## Features of Our Products\n\n1. **High Activation Efficiency**  \n   Our CRISPRa platform integrates optimized gRNA design and advanced activator domains to achieve **strong and consistent gene upregulation**.\n\n2. **Multiple Delivery Options**  \n   Available in both **lentiviral** and **plasmid** formats, allowing **flexible delivery** to a wide range of cell types, including difficult-to-transfect cells.\n\n3. **All-in-One or Standalone Configurations**  \n   Choose between **all-in-one** and **standalone** formats to suit your experimental needs:  \n   - **All-in-One**: Cas9 activator and gRNA cassettes are integrated into a single vector for streamlined transfection and stable expression.  \n   - **Standalone**: Cas9 activator and gRNA are provided on separate plasmids, offering greater modularity and experimental control.\n\n4. **Comprehensive Kit Design**  \n   Each kit contains **three gRNA vectors** targeting the gene of interest and **one scramble control**, ensuring reliable results with appropriate experimental controls.\n","keyFeatures":[],"availability":"In Stock","optionPrices":{},"catalogNumber":"GEX-006","showInFeatured":false,"dataDescription":"","performanceData":"","storageStability":"","showInGeneEditing":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('32', 'custom-1759625091045', 'CRISPR Inhibition Kit', 'The CRISPR Inhibition (CRISPRi) Kit enables precise, reversible downregulation of target gene expression without altering DNA sequences. Utilizing a nuclease-deactivated Cas9 (dCas9) fused with potent transcriptional repressors, this system offers a robust tool for functional genomics, pathway analysis, and loss-of-function studies. Each kit includes three target-specific gRNA vectors and one scramble control, available in all-in-one or standalone formats for flexible experimental design.', '/content-api/uploads/originals/d93c6340-fa2f-4545-b855-e1d8744cf268.png', '/products/crispr-inhibition', 'genome-editing', 'DNA', 'quote', 6, '1759625091045', '2025-10-05T00:44:51.045Z', 'GEX-005', 'In Stock', '', '$799', TRUE, FALSE, FALSE, TRUE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', '', ARRAY[], ARRAY[], ARRAY['/content-api/uploads/originals/d93c6340-fa2f-4545-b855-e1d8744cf268.png'], 'https://store.bioarktech.com/cart', '
**CRISPR inhibition (CRISPRi)** is an advanced gene-regulation technology that enables researchers to **downregulate or silence the expression** of target genes **without altering the underlying DNA sequence**.  

Unlike CRISPR knockout, which introduces double-strand breaks to disrupt gene function, CRISPRi employs a **nuclease-deactivated Cas9 (dCas9)** fused to **transcriptional repressors**, allowing **precise and reversible suppression of gene expression**.  

Our system provides a **rapid, efficient, and reversible** approach to inhibit gene expression—ideal for **functional genomics**, **pathway analysis**, and **loss-of-function studies** in therapeutic research.

---

## Technical Background

1. **dCas9 Protein**  
   A catalytically inactive Cas9 variant that binds to specific genomic loci guided by gRNA, without inducing double-strand breaks.  

2. **Guide RNA (gRNA)**  
   A short RNA sequence that directs dCas9 to the **promoter or regulatory region** of a target gene, enabling **site-specific transcriptional repression**.  

3. **Transcriptional Repressors**  
   - **KRAB or SID domains**: Potent repressor domains that recruit chromatin-modifying complexes to inhibit transcriptional initiation.  
   - **Combinatorial systems (optional)**: Enhanced multi-component repression systems (e.g., **dCas9-KRAB-MeCP2**) for stronger gene silencing.  

By precisely positioning **dCas9-repressor complexes** near promoter regions, researchers can **block transcription initiation or elongation**, enabling **fine-tuned control** of endogenous gene suppression for mechanistic studies or phenotype screening.

---

## Features of Our Products

1. **High Repression Efficiency**  
   Our CRISPRi platform integrates optimized gRNA design and advanced repressor domains to achieve **strong and consistent gene downregulation**.  

2. **Multiple Delivery Options**  
   Available in both **lentiviral** and **plasmid** formats, allowing **flexible delivery** to a wide range of cell types, including difficult-to-transfect cells.  

3. **All-in-One or Standalone Configurations**  
   Choose between **all-in-one** and **standalone** formats to suit your experimental needs:  
   - **All-in-One**: Cas9 repressor and gRNA cassettes are integrated into a single vector for streamlined transfection and stable expression.  
   - **Standalone**: Cas9 repressor and gRNA are provided on separate plasmids, offering greater modularity and experimental control.  

4. **Comprehensive Kit Design**  
   Each kit contains **three gRNA vectors** targeting the gene of interest and **one scramble control**, ensuring **reliable results** with appropriate experimental controls.
', FALSE, '{"id":"custom-1759625091045","link":"/products/crispr-inhibition","name":"CRISPR Inhibition Kit","order":6,"__type":"quote","category":"genome-editing","imageUrl":"","createdAt":1759625091045,"description":"The CRISPR Inhibition (CRISPRi) Kit enables precise, reversible downregulation of target gene expression without altering DNA sequences. Utilizing a nuclease-deactivated Cas9 (dCas9) fused with potent transcriptional repressors, this system offers a robust tool for functional genomics, pathway analysis, and loss-of-function studies. Each kit includes three target-specific gRNA vectors and one scramble control, available in all-in-one or standalone formats for flexible experimental design."}'::jsonb, NULL, '{"images":["/content-api/uploads/originals/d93c6340-fa2f-4545-b855-e1d8744cf268.png"],"manuals":[],"options":[],"createdAt":1759625091045,"listPrice":"","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"priceRange":"$799","contentText":"\n**CRISPR inhibition (CRISPRi)** is an advanced gene-regulation technology that enables researchers to **downregulate or silence the expression** of target genes **without altering the underlying DNA sequence**.  \n\nUnlike CRISPR knockout, which introduces double-strand breaks to disrupt gene function, CRISPRi employs a **nuclease-deactivated Cas9 (dCas9)** fused to **transcriptional repressors**, allowing **precise and reversible suppression of gene expression**.  \n\nOur system provides a **rapid, efficient, and reversible** approach to inhibit gene expression—ideal for **functional genomics**, **pathway analysis**, and **loss-of-function studies** in therapeutic research.\n\n---\n\n## Technical Background\n\n1. **dCas9 Protein**  \n   A catalytically inactive Cas9 variant that binds to specific genomic loci guided by gRNA, without inducing double-strand breaks.  \n\n2. **Guide RNA (gRNA)**  \n   A short RNA sequence that directs dCas9 to the **promoter or regulatory region** of a target gene, enabling **site-specific transcriptional repression**.  \n\n3. **Transcriptional Repressors**  \n   - **KRAB or SID domains**: Potent repressor domains that recruit chromatin-modifying complexes to inhibit transcriptional initiation.  \n   - **Combinatorial systems (optional)**: Enhanced multi-component repression systems (e.g., **dCas9-KRAB-MeCP2**) for stronger gene silencing.  \n\nBy precisely positioning **dCas9-repressor complexes** near promoter regions, researchers can **block transcription initiation or elongation**, enabling **fine-tuned control** of endogenous gene suppression for mechanistic studies or phenotype screening.\n\n---\n\n## Features of Our Products\n\n1. **High Repression Efficiency**  \n   Our CRISPRi platform integrates optimized gRNA design and advanced repressor domains to achieve **strong and consistent gene downregulation**.  \n\n2. **Multiple Delivery Options**  \n   Available in both **lentiviral** and **plasmid** formats, allowing **flexible delivery** to a wide range of cell types, including difficult-to-transfect cells.  \n\n3. **All-in-One or Standalone Configurations**  \n   Choose between **all-in-one** and **standalone** formats to suit your experimental needs:  \n   - **All-in-One**: Cas9 repressor and gRNA cassettes are integrated into a single vector for streamlined transfection and stable expression.  \n   - **Standalone**: Cas9 repressor and gRNA are provided on separate plasmids, offering greater modularity and experimental control.  \n\n4. **Comprehensive Kit Design**  \n   Each kit contains **three gRNA vectors** targeting the gene of interest and **one scramble control**, ensuring **reliable results** with appropriate experimental controls.\n","keyFeatures":[],"availability":"In Stock","optionPrices":{},"catalogNumber":"GEX-005","showInFeatured":false,"dataDescription":"","performanceData":"","storageStability":"","showInGeneEditing":true}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('33', 'lv-01', 'Lentivirus ORF Stock', 'cDNA-expressing lentiviral stocks for gene delivery.', '/placeholder.svg', '/products/cdna-lentivirus-stock', 'lentivirus', 'LentiVirus', 'quote', 7, NULL, NULL, 'LV-001', 'In Stock', 'Contact for Quote', '', TRUE, FALSE, FALSE, FALSE, ARRAY['High titer', 'Sterile filtered', 'QC validated'], ARRAY[], '{}'::jsonb, 'Store at -80°C. Avoid repeated freeze-thaw cycles.', 'Infectivity verified in standard cell lines.', '', ARRAY['Lentivirus User Guide (PDF)'], ARRAY[], ARRAY['/placeholder.svg'], '', '# BioArk Technologies

BioArk Technologies is continuously expanding its collection of cDNA lentivirus stocks, offering an ever-growing selection of specific genes and targets. Our mission is to provide high-quality, pre-packaged lentiviruses at an affordable price while promoting scientific collaboration and resource sharing.

Explore our expanding list of cost-effective, pre-constructed lentiviruses here.

---

| Major Vector | | | Donor Vector | | | Scramble Control Vector | | |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **Class** | **Product Name** | **SKU** | **Information** | **Donor Name** | **SKU** | **Information** | **Scramble Name** | **SKU** | **Information** |
| Non-Viral CDS-P011k | CRISPR KN AIO Kit-Gene AAVS1, Vector type | COT-FXD00A-AAVS1gk | The CRISPR tool specifically designed to target and cut human AAVS1 safe harbor site. | AAVS1 Dnr Std Kit | CDS-FX00PA-XXXXXXk | Insert Customer Gene into human AAVS1 site, please specify your genes by clicking the button | GFP Donor Control AAVS1 Dnr Std Ctrl Kit, vector type | CDS-FX0GPA-000000k | Insert GFP into human AAVS1 site as control |
| Non-Viral CDS-P011k | CRISPR KN AIO Kit-Gene ROSA26, Vector type | COT-FXD00A-ROSA26gk | The CRISPR tool specifically designed to target and cut mouse ROSA26 safe harbor site. | Dnr Std Kit-ROSA26 Site | TBD | Insert Customer Gene into mouse ROSA26 site, please specify your custom gene by clicking the button | GFP Donor Control Dnr Std Kit-ROSA26 Site, vector type | TBD | Insert GFP into mouse ROSA26 site as control |

*Showing 1 to 3 of 3 entries*

---

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.
```', FALSE, '{"id":"lv-01"}'::jsonb, '{"link":"/products/cdna-lentivirus-stock","name":"Lentivirus ORF Stock","order":7,"__type":"quote","category":"lentivirus","description":"cDNA-expressing lentiviral stocks for gene delivery."}'::jsonb, '{"images":["/placeholder.svg"],"manuals":["Lentivirus User Guide (PDF)"],"options":[],"listPrice":"Contact for Quote","quoteOnly":true,"storeLink":"","manualUrls":[],"priceRange":"","contentText":"# BioArk Technologies\n\nBioArk Technologies is continuously expanding its collection of cDNA lentivirus stocks, offering an ever-growing selection of specific genes and targets. Our mission is to provide high-quality, pre-packaged lentiviruses at an affordable price while promoting scientific collaboration and resource sharing.\n\nExplore our expanding list of cost-effective, pre-constructed lentiviruses here.\n\n---\n\n| Major Vector | | | Donor Vector | | | Scramble Control Vector | | |\n| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |\n| **Class** | **Product Name** | **SKU** | **Information** | **Donor Name** | **SKU** | **Information** | **Scramble Name** | **SKU** | **Information** |\n| Non-Viral CDS-P011k | CRISPR KN AIO Kit-Gene AAVS1, Vector type | COT-FXD00A-AAVS1gk | The CRISPR tool specifically designed to target and cut human AAVS1 safe harbor site. | AAVS1 Dnr Std Kit | CDS-FX00PA-XXXXXXk | Insert Customer Gene into human AAVS1 site, please specify your genes by clicking the button | GFP Donor Control AAVS1 Dnr Std Ctrl Kit, vector type | CDS-FX0GPA-000000k | Insert GFP into human AAVS1 site as control |\n| Non-Viral CDS-P011k | CRISPR KN AIO Kit-Gene ROSA26, Vector type | COT-FXD00A-ROSA26gk | The CRISPR tool specifically designed to target and cut mouse ROSA26 safe harbor site. | Dnr Std Kit-ROSA26 Site | TBD | Insert Customer Gene into mouse ROSA26 site, please specify your custom gene by clicking the button | GFP Donor Control Dnr Std Kit-ROSA26 Site, vector type | TBD | Insert GFP into mouse ROSA26 site as control |\n\n*Showing 1 to 3 of 3 entries*\n\n---\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.\n```","keyFeatures":["High titer","Sterile filtered","QC validated"],"availability":"In Stock","optionPrices":{},"catalogNumber":"LV-001","showInFeatured":false,"dataDescription":"","performanceData":"Infectivity verified in standard cell lines.","storageStability":"Store at -80°C. Avoid repeated freeze-thaw cycles.","showInGeneEditing":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('34', 'sc-01', 'Stable Cell Line Stock', 'Ready-to-use stable cell line stocks for research applications.', '/placeholder.svg', '/products/stable-cell-line-stock', 'stable-cell-lines', NULL, 'quote', 8, NULL, NULL, 'SC-001', 'In Stock', 'Contact for Quote', NULL, TRUE, FALSE, FALSE, FALSE, ARRAY['Authenticated', 'Mycoplasma-tested', 'Application-ready'], ARRAY[], '{}'::jsonb, 'Store in liquid nitrogen or as specified.', 'QC documentation available upon request.', NULL, ARRAY['Cell Line Handling Guide (PDF)'], ARRAY[], ARRAY['/placeholder.svg'], '', '# BioArk Technologies

BioArk Technologies is continuously expanding its stable cell line stock, offering an ever-growing selection of gene-specific modifications. Our mission is to provide high-quality, pre-validated stable cell lines at an affordable price while fostering scientific collaboration and resource sharing.

Explore our expanding list of cost-effective, pre-constructed stable cell lines here.

---

| Stable Cell Line | | | Gene Editing Feature | | | | |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **Product Name** | **SKU** | **Description** | **Promoter** | **Protein Tag** | **Fluorescence Marker** | **Selection Marker** | **Target Gene** | **Cell Background** |
| OverExp Lenti Kit | EML-CXD0PC-LARGETc | The large T antigen is integrated by lentivirus | PCMV | MycDDK | None | Puro | LargeT | Fibroblast Cells |

*Showing 1 to 2 of 2 entries*

---

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.

If you have any further inquiries regarding your project, please click the button to contact us. We are fully equipped to accommodate a wide range of your requirements.
```', FALSE, '{"id":"sc-01"}'::jsonb, '{"link":"/products/stable-cell-line-stock","name":"Stable Cell Line Stock","order":8,"__type":"quote","category":"stable-cell-lines","description":"Ready-to-use stable cell line stocks for research applications."}'::jsonb, '{"images":["/placeholder.svg"],"manuals":["Cell Line Handling Guide (PDF)"],"options":[],"listPrice":"Contact for Quote","quoteOnly":true,"storeLink":"","manualUrls":[],"contentText":"# BioArk Technologies\n\nBioArk Technologies is continuously expanding its stable cell line stock, offering an ever-growing selection of gene-specific modifications. Our mission is to provide high-quality, pre-validated stable cell lines at an affordable price while fostering scientific collaboration and resource sharing.\n\nExplore our expanding list of cost-effective, pre-constructed stable cell lines here.\n\n---\n\n| Stable Cell Line | | | Gene Editing Feature | | | | |\n| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |\n| **Product Name** | **SKU** | **Description** | **Promoter** | **Protein Tag** | **Fluorescence Marker** | **Selection Marker** | **Target Gene** | **Cell Background** |\n| OverExp Lenti Kit | EML-CXD0PC-LARGETc | The large T antigen is integrated by lentivirus | PCMV | MycDDK | None | Puro | LargeT | Fibroblast Cells |\n\n*Showing 1 to 2 of 2 entries*\n\n---\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.\n\nIf you have any further inquiries regarding your project, please click the button to contact us. We are fully equipped to accommodate a wide range of your requirements.\n```","keyFeatures":["Authenticated","Mycoplasma-tested","Application-ready"],"availability":"In Stock","optionPrices":{},"catalogNumber":"SC-001","performanceData":"QC documentation available upon request.","storageStability":"Store in liquid nitrogen or as specified."}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('35', 'custom-1759879837546', 'Non-Viral RNAi Vector', 'A high-efficiency, non-viral RNAi plasmid designed for customizable, stable, or transient gene silencing in mammalian cells.', '/content-api/uploads/originals/c5ac4a80-c1b8-4a65-bfd6-2cff30793e96.png', '/products/nonviral-rnai-template', 'vector-clones', 'Non-Viral', 'quote', 9, '1759879837546', '2025-10-07T23:30:37.546Z', 'SHS-UX00PA', 'Ready To Order', '', '$299', TRUE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', 'Support Documents', ARRAY[], ARRAY[], ARRAY['/content-api/uploads/originals/c5ac4a80-c1b8-4a65-bfd6-2cff30793e96.png', '/content-api/uploads/originals/5a8011d4-06aa-45d6-ab93-9ae692c8f9d6.png', '/content-api/uploads/originals/ae36de5d-e9fe-4dbb-837d-cb8198b45646.png', '/content-api/uploads/originals/9c956c8c-5f7c-45e2-a3e5-87807324aea3.png', '/content-api/uploads/originals/0c525c15-a111-4c49-9d2c-c80046c7cf79.png', '/content-api/uploads/originals/dbd48ede-551b-491d-99ea-aa75f96d11c8.png', '/content-api/uploads/originals/eb9cef4a-5e19-4224-a6fc-adcc03ad13a1.png', '/content-api/uploads/originals/f3740117-de84-456d-bce5-c2e8191c5d6e.png'], 'https://store.bioarktech.com/cart', '# Product Description

Our **Non-Viral RNAi Plasmid** provides a **flexible and efficient solution** for **stable or transient gene silencing** in mammalian cells.  
Designed for **high-efficiency RNA interference (RNAi)**, this plasmid enables researchers to easily **clone**, **express**, and **evaluate shRNA or miRNA constructs** targeting genes of interest—**without the use of viral vectors**.  

The system supports a wide range of **functional genomics** and **molecular biology** applications, including **loss-of-function studies**, **pathway analysis**, and **phenotypic screening**.  

---

# Key Features

- 🔹 **High-Efficiency Gene Silencing**  
  Optimized expression of **shRNA or miRNA sequences** under strong **U6** or **H1 promoters** ensures robust and consistent knockdown of target genes.  

- 🔹 **Customizable Promoter Options**  
  Combine **RNA Pol III promoters (U6/H1)** with **constitutive Pol II promoters** (e.g., **CMV**, **EF1α**, **CAG**) for **dual-expression systems** or **regulated knockdown**.  

- 🔹 **Selectable Markers**  
  Available with **Puromycin**, **Neomycin (G418)**, **Blasticidin**, or **Hygromycin** resistance cassettes for **stable cell selection** in various cell types.  

- 🔹 **Fluorescent Reporter Integration**  
  Optional **GFP**, **RFP**, **BFP**, or **mCherry** reporters allow easy monitoring of **transfection efficiency** and **cell selection**.  

- 🔹 **Cloning Flexibility**  
  Supports **multiple cloning sites (MCS)** and is compatible with **Gateway®** or **Gibson Assembly®**, streamlining the insertion of **custom RNAi sequences**.  

- 🔹 **Non-Viral and Safe**  
  Completely **non-viral**, avoiding biosafety concerns, and ideal for **in vitro** and **preclinical research applications**.  

---

# Applications

- **Gene knockdown** and **loss-of-function** studies  
- **Functional genomics** and **pathway dissection**  
- **Target validation** and **drug screening**  
- **Phenotypic screening** for gene function analysis  
- **Reporter-based assays** for silencing efficiency evaluation
', FALSE, '{"id":"custom-1759879837546","link":"/products/nonviral-rnai-template","name":"Non-Viral RNAi Vector","order":9,"__type":"quote","category":"vector-clones","imageUrl":"","createdAt":1759879837546,"description":"A high-efficiency, non-viral RNAi plasmid designed for customizable, stable, or transient gene silencing in mammalian cells."}'::jsonb, NULL, '{"images":["/content-api/uploads/originals/c5ac4a80-c1b8-4a65-bfd6-2cff30793e96.png","/content-api/uploads/originals/5a8011d4-06aa-45d6-ab93-9ae692c8f9d6.png","/content-api/uploads/originals/ae36de5d-e9fe-4dbb-837d-cb8198b45646.png","/content-api/uploads/originals/9c956c8c-5f7c-45e2-a3e5-87807324aea3.png","/content-api/uploads/originals/0c525c15-a111-4c49-9d2c-c80046c7cf79.png","/content-api/uploads/originals/dbd48ede-551b-491d-99ea-aa75f96d11c8.png","/content-api/uploads/originals/eb9cef4a-5e19-4224-a6fc-adcc03ad13a1.png","/content-api/uploads/originals/f3740117-de84-456d-bce5-c2e8191c5d6e.png"],"manuals":[],"options":[],"createdAt":1759879837546,"listPrice":"","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"priceRange":"$299","contentText":"# Product Description\n\nOur **Non-Viral RNAi Plasmid** provides a **flexible and efficient solution** for **stable or transient gene silencing** in mammalian cells.  \nDesigned for **high-efficiency RNA interference (RNAi)**, this plasmid enables researchers to easily **clone**, **express**, and **evaluate shRNA or miRNA constructs** targeting genes of interest—**without the use of viral vectors**.  \n\nThe system supports a wide range of **functional genomics** and **molecular biology** applications, including **loss-of-function studies**, **pathway analysis**, and **phenotypic screening**.  \n\n---\n\n# Key Features\n\n- 🔹 **High-Efficiency Gene Silencing**  \n  Optimized expression of **shRNA or miRNA sequences** under strong **U6** or **H1 promoters** ensures robust and consistent knockdown of target genes.  \n\n- 🔹 **Customizable Promoter Options**  \n  Combine **RNA Pol III promoters (U6/H1)** with **constitutive Pol II promoters** (e.g., **CMV**, **EF1α**, **CAG**) for **dual-expression systems** or **regulated knockdown**.  \n\n- 🔹 **Selectable Markers**  \n  Available with **Puromycin**, **Neomycin (G418)**, **Blasticidin**, or **Hygromycin** resistance cassettes for **stable cell selection** in various cell types.  \n\n- 🔹 **Fluorescent Reporter Integration**  \n  Optional **GFP**, **RFP**, **BFP**, or **mCherry** reporters allow easy monitoring of **transfection efficiency** and **cell selection**.  \n\n- 🔹 **Cloning Flexibility**  \n  Supports **multiple cloning sites (MCS)** and is compatible with **Gateway®** or **Gibson Assembly®**, streamlining the insertion of **custom RNAi sequences**.  \n\n- 🔹 **Non-Viral and Safe**  \n  Completely **non-viral**, avoiding biosafety concerns, and ideal for **in vitro** and **preclinical research applications**.  \n\n---\n\n# Applications\n\n- **Gene knockdown** and **loss-of-function** studies  \n- **Functional genomics** and **pathway dissection**  \n- **Target validation** and **drug screening**  \n- **Phenotypic screening** for gene function analysis  \n- **Reporter-based assays** for silencing efficiency evaluation\n","keyFeatures":[],"availability":"Ready To Order","optionPrices":{},"catalogNumber":"SHS-UX00PA","showInFeatured":false,"dataDescription":"Support Documents","performanceData":"","storageStability":"","showInGeneEditing":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('36', 'custom-1759628557002', 'Non-Viral CDS Vector', 'he Non-Viral Overexpression Plasmid System enables efficient, customizable expression of target genes in mammalian cells without the use of viral vectors. Designed for flexibility, the plasmids support multiple promoters (CMV, EF1α, CAG), selection markers (Puromycin, Neomycin, Blasticidin, Hygromycin), fluorescent reporters (GFP, RFP, mCherry), and epitope tags (FLAG, HA, Myc, His), providing a versatile solution for gene function studies, protein production, and pathway analysis.', '/content-api/uploads/originals/25856f6f-df8b-42cb-8790-08f8091b19eb.png', '/products/non-viral-gene-overexpression-plasmid-template', 'vector-clones', 'Non-Viral', 'quote', 10, '1759628557002', '2025-10-05T01:42:37.002Z', 'EMS-FXD0PA', 'Ready To Order', '$299+syn.', '$299', TRUE, FALSE, FALSE, FALSE, ARRAY[], ARRAY[], '{}'::jsonb, '', '', 'Support Documents', ARRAY[], ARRAY[], ARRAY['/content-api/uploads/originals/25856f6f-df8b-42cb-8790-08f8091b19eb.png', '/content-api/uploads/originals/9d798728-5315-48cf-bed6-83c1de4feddc.png', '/content-api/uploads/originals/caa1b243-6768-417c-9131-8c7e8f967f3a.png', '/content-api/uploads/originals/795dcbd2-9c3b-491c-9118-e2d7525948f5.png', '/content-api/uploads/originals/70d782c7-d888-44ba-94f4-40416e698028.png', '/content-api/uploads/originals/6891d83d-8628-40f2-bcec-67adc4a2e61d.png', '/content-api/uploads/originals/cd084f52-788c-46df-b93e-9e884cbbbedd.png', '/content-api/uploads/originals/319edd09-18f2-4299-961d-fc1deca74c6d.png'], 'https://store.bioarktech.com/cart', '# Non-Viral Overexpression Plasmid

Our **Non-Viral Overexpression Plasmid** provides a **flexible and efficient solution** for **stable or transient expression** of genes of interest in mammalian cells.  
Designed for **high-level, customizable gene expression**, this plasmid enables researchers to easily **clone, express, and analyze** target genes **without the use of viral vectors**.  

The system supports a wide range of **molecular biology** and **functional genomics applications**, including **protein production**, **pathway studies**, **phenotypic screening**, and **functional validation**.

---

## Key Features

- 🔹 **Versatile Expression Control**  
  Choose from **strong constitutive promoters** (e.g., CMV, EF1α, CAG, or PGK) for customized regulation of target gene expression.  

- 🔹 **Customizable Selection Markers**  
  Available with a variety of **antibiotic resistance genes**, including **Puromycin**, **Neomycin (G418)**, **Blasticidin**, or **Hygromycin**, for flexible selection across cell types.  

- 🔹 **Fluorescent Reporter Options**  
  Integrated **fluorescent markers** (e.g., GFP, miniGFP, RFP, BFP, mCherry) facilitate **real-time tracking** of transfection efficiency and expression.  

- 🔹 **Tag Integration**  
  Support for **epitope tags** such as **FLAG**, **HA**, **Myc**, or **His**, enabling downstream **detection**, **purification**, or **localization** studies.  

- 🔹 **Multiple Cloning and Compatibility**  
  Engineered with **multiple cloning sites (MCS)** and optional **Gateway®** or **Gibson Assembly®** compatibility for efficient gene insertion.  

- 🔹 **Non-Viral and Safe**  
  Eliminates **biosafety concerns** associated with viral delivery, suitable for both **in vitro** and **preclinical** research applications.  

---

## Applications

- Gene and protein overexpression studies  
- Functional genomics and pathway analysis  
- Recombinant protein production  
- Drug screening and target validation  
- Fluorescence-based cell tracking


', FALSE, '{"id":"custom-1759628557002","link":"/products/non-viral-gene-overexpression-plasmid-template","name":"Non-Viral CDS Vector","order":10,"__type":"quote","category":"vector-clones","imageUrl":"","createdAt":1759628557002,"description":"he Non-Viral Overexpression Plasmid System enables efficient, customizable expression of target genes in mammalian cells without the use of viral vectors. Designed for flexibility, the plasmids support multiple promoters (CMV, EF1α, CAG), selection markers (Puromycin, Neomycin, Blasticidin, Hygromycin), fluorescent reporters (GFP, RFP, mCherry), and epitope tags (FLAG, HA, Myc, His), providing a versatile solution for gene function studies, protein production, and pathway analysis."}'::jsonb, NULL, '{"images":["/content-api/uploads/originals/25856f6f-df8b-42cb-8790-08f8091b19eb.png","/content-api/uploads/originals/9d798728-5315-48cf-bed6-83c1de4feddc.png","/content-api/uploads/originals/caa1b243-6768-417c-9131-8c7e8f967f3a.png","/content-api/uploads/originals/795dcbd2-9c3b-491c-9118-e2d7525948f5.png","/content-api/uploads/originals/70d782c7-d888-44ba-94f4-40416e698028.png","/content-api/uploads/originals/6891d83d-8628-40f2-bcec-67adc4a2e61d.png","/content-api/uploads/originals/cd084f52-788c-46df-b93e-9e884cbbbedd.png","/content-api/uploads/originals/319edd09-18f2-4299-961d-fc1deca74c6d.png"],"manuals":[],"options":[],"createdAt":1759628557002,"listPrice":"$299+syn.","quoteOnly":true,"storeLink":"https://store.bioarktech.com/cart","manualUrls":[],"priceRange":"$299","contentText":"# Non-Viral Overexpression Plasmid\n\nOur **Non-Viral Overexpression Plasmid** provides a **flexible and efficient solution** for **stable or transient expression** of genes of interest in mammalian cells.  \nDesigned for **high-level, customizable gene expression**, this plasmid enables researchers to easily **clone, express, and analyze** target genes **without the use of viral vectors**.  \n\nThe system supports a wide range of **molecular biology** and **functional genomics applications**, including **protein production**, **pathway studies**, **phenotypic screening**, and **functional validation**.\n\n---\n\n## Key Features\n\n- 🔹 **Versatile Expression Control**  \n  Choose from **strong constitutive promoters** (e.g., CMV, EF1α, CAG, or PGK) for customized regulation of target gene expression.  \n\n- 🔹 **Customizable Selection Markers**  \n  Available with a variety of **antibiotic resistance genes**, including **Puromycin**, **Neomycin (G418)**, **Blasticidin**, or **Hygromycin**, for flexible selection across cell types.  \n\n- 🔹 **Fluorescent Reporter Options**  \n  Integrated **fluorescent markers** (e.g., GFP, miniGFP, RFP, BFP, mCherry) facilitate **real-time tracking** of transfection efficiency and expression.  \n\n- 🔹 **Tag Integration**  \n  Support for **epitope tags** such as **FLAG**, **HA**, **Myc**, or **His**, enabling downstream **detection**, **purification**, or **localization** studies.  \n\n- 🔹 **Multiple Cloning and Compatibility**  \n  Engineered with **multiple cloning sites (MCS)** and optional **Gateway®** or **Gibson Assembly®** compatibility for efficient gene insertion.  \n\n- 🔹 **Non-Viral and Safe**  \n  Eliminates **biosafety concerns** associated with viral delivery, suitable for both **in vitro** and **preclinical** research applications.  \n\n---\n\n## Applications\n\n- Gene and protein overexpression studies  \n- Functional genomics and pathway analysis  \n- Recombinant protein production  \n- Drug screening and target validation  \n- Fluorescence-based cell tracking\n\n\n","keyFeatures":[],"availability":"Ready To Order","optionPrices":{},"catalogNumber":"EMS-FXD0PA","showInFeatured":false,"dataDescription":"Support Documents","performanceData":"","storageStability":"","showInGeneEditing":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z'),
    ('37', 'lv-02', 'Lentivirus Control Stock', 'Control lentiviral stocks for assay validation and benchmarking.', '/placeholder.svg', '/products/lentivirus-control-stock', 'lentivirus', 'LentiVirus', 'quote', 12, NULL, NULL, 'LV-002', 'In Stock', 'Contact for Quote', '', TRUE, FALSE, FALSE, FALSE, ARRAY['Positive/negative controls', 'Consistent titers', 'Ready-to-use'], ARRAY[], '{}'::jsonb, 'Store at -80°C. Avoid repeated freeze-thaw cycles.', 'Validated for use across common cell lines.', '', ARRAY['Control Stock Guide (PDF)'], ARRAY[], ARRAY['/placeholder.svg'], '', '# BioArk Technologies

BioArk Technologies is continuously expanding its collection of cDNA lentivirus stocks, offering a growing selection of control lentiviruses for various research applications. Our mission is to provide high-quality, pre-packaged lentiviruses at an affordable price while fostering scientific collaboration and resource sharing.

Explore our expanding list of cost-effective, pre-constructed lentivirus controls [here](#).

---

## Lentivirus Controls Catalog

| Category        | Class               | Product Name                              | SKU                     | Accessory Virus | Promoter   | Protein Tag | Fluorescence Marker | Selection Marker |
|-----------------|---------------------|-------------------------------------------|-------------------------|-----------------|------------|-------------|---------------------|------------------|
| Overexpression  | Viral All-in-one    | OverExp Lenti Ctrl Kit, lentivirus type   | EML-CXDG0C-000000l      | None            | PCMV       | MycDDK      | GFP                 | None             |
| Inducible       | Viral All-in-one    | Inducible Lenti-AIO Ctrl Kit, lentivirus type | IMM-DXDGPC-000000l  | None            | Inducible  | MycDDK      | GFP                 | Puro             |

*Showing 1 to 3 of 3 entries*  
*10 entries per page*  
*Search functionality available*

---

Our design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.
```', FALSE, '{"id":"lv-02"}'::jsonb, '{"link":"/products/lentivirus-control-stock","name":"Lentivirus Control Stock","order":12,"__type":"quote","category":"lentivirus","description":"Control lentiviral stocks for assay validation and benchmarking."}'::jsonb, '{"images":["/placeholder.svg"],"manuals":["Control Stock Guide (PDF)"],"options":[],"listPrice":"Contact for Quote","quoteOnly":true,"storeLink":"","manualUrls":[],"priceRange":"","contentText":"# BioArk Technologies\n\nBioArk Technologies is continuously expanding its collection of cDNA lentivirus stocks, offering a growing selection of control lentiviruses for various research applications. Our mission is to provide high-quality, pre-packaged lentiviruses at an affordable price while fostering scientific collaboration and resource sharing.\n\nExplore our expanding list of cost-effective, pre-constructed lentivirus controls [here](#).\n\n---\n\n## Lentivirus Controls Catalog\n\n| Category        | Class               | Product Name                              | SKU                     | Accessory Virus | Promoter   | Protein Tag | Fluorescence Marker | Selection Marker |\n|-----------------|---------------------|-------------------------------------------|-------------------------|-----------------|------------|-------------|---------------------|------------------|\n| Overexpression  | Viral All-in-one    | OverExp Lenti Ctrl Kit, lentivirus type   | EML-CXDG0C-000000l      | None            | PCMV       | MycDDK      | GFP                 | None             |\n| Inducible       | Viral All-in-one    | Inducible Lenti-AIO Ctrl Kit, lentivirus type | IMM-DXDGPC-000000l  | None            | Inducible  | MycDDK      | GFP                 | Puro             |\n\n*Showing 1 to 3 of 3 entries*  \n*10 entries per page*  \n*Search functionality available*\n\n---\n\nOur design program assists customers in adjusting vector components and developing specific functions tailored to their unique requirements.\n```","keyFeatures":["Positive/negative controls","Consistent titers","Ready-to-use"],"availability":"In Stock","optionPrices":{},"catalogNumber":"LV-002","showInFeatured":false,"dataDescription":"","performanceData":"Validated for use across common cell lines.","storageStability":"Store at -80°C. Avoid repeated freeze-thaw cycles.","showInGeneEditing":false}'::jsonb, '2026-06-19T01:30:24.896Z', '2026-06-19T01:30:24.896Z');

CREATE INDEX idx_product_catalog_number ON public.product USING btree (catalog_number);
CREATE INDEX idx_product_category_external_id ON public.product USING btree (category_external_id);
CREATE INDEX idx_product_display_order ON public.product USING btree (display_order);
CREATE INDEX idx_product_show_in_featured ON public.product USING btree (show_in_featured) WHERE (show_in_featured = true);
SELECT setval(pg_get_serial_sequence('public.product', 'product_id'), COALESCE((SELECT MAX("product_id") FROM public."product"), 1), true);

-- ============================================================
-- public.blog
-- ============================================================
DROP TABLE IF EXISTS public."blog" CASCADE;
CREATE TABLE IF NOT EXISTS public."blog" (
    "id" bigint NOT NULL,
    "title" character varying(200) NOT NULL,
    "author" character varying(30) NOT NULL,
    "image" character varying(100),
    "date_posted" timestamp with time zone NOT NULL,
    "date_modified" timestamp with time zone NOT NULL,
    "content" text NOT NULL,
    "description" character varying(150) NOT NULL,
    CONSTRAINT "blog_pkey" PRIMARY KEY (id)
);

INSERT INTO public."blog" ("id", "title", "author", "image", "date_posted", "date_modified", "content", "description") VALUES
    ('1765571538185', 'CRISPR Gene Editing: Best Practices, Delivery Strategies, and Clinical Applications', 'Admin', '/content-api/uploads/originals/c4f93624-61a3-4ee9-82e1-02d97b8c0ead.jpg', '2025-12-12T00:00:00.000Z', '2026-06-18T20:31:02.302Z', '## Recent Progress in CRISPR Technology and Its Applications

The last two years have been defined less by new editing chemistries and more by what actually gets editors where they need to go—and how we prove it. Delivery decisions, disciplined assay design, and realistic clinical translation constraints have become the center of gravity for CRISPR programs. If you’re making 2025 plans, the question isn’t “which editor is best?” but “which delivery route yields reproducible, regulated outcomes for this tissue and payload—under real-world constraints?”

[https://www.youtube.com/watch?v=TChOfKAjeAg](https://www.youtube.com/watch?v=TChOfKAjeAg)




## Delivery is the Decider: What 2024–2025 Really Changed

Head-to-head clinical comparisons across delivery modalities are still rare, yet pragmatic benchmarks have sharpened. Most in vivo human data remain liver-centric via LNP, while AAV advances are concentrated in local, nondividing tissues. Ex vivo electroporation continues to be the workhorse in hematology. VLPs and physical/field-based approaches show promise but lack human clinical editing metrics.

### LNP for systemic liver targets

LNPs dominate systemic in vivo delivery to hepatocytes due to natural uptake and scalable formulation workflows. Human programs have reported substantial, dose-dependent target protein reductions with generally transient infusion reactions and hepatic lab changes. The FDA’s 2025 clinical hold on two late-stage in vivo CRISPR trials after a grade‑4 liver-related event underscores the need for conservative dosing, predefined thresholds, and robust hepatic safety plans, as summarized by BioPharmaDive in October 2025: see the agency’s hold announcement and context in the [**Intellia phase 3 hold coverage (BioPharmaDive, 2025)**](https://www.biopharmadive.com/news/intellia-fda-clinical-hold-crispr-nexiguran-ziclumeran-ttr-amyloidosis/804229/).

### AAV for local/nondividing tissues

AAV remains a strong choice for ocular and localized CNS delivery, particularly where tight tissue tropism and long-term expression are desirable. A 2025 peer-reviewed analysis cataloged serotype-dependent tropism and practical co‑transduction efficiencies relevant to split-cargo CRISPR; see the field’s synthesis in the [**Nature Gene Therapy rAAV delivery review (2025; PubMed)**](https://pubmed.ncbi.nlm.nih.gov/41224955/) and detailed dual‑AAV retina co‑transduction data in [**the 2025 retina study (PMC)**](https://pmc.ncbi.nlm.nih.gov/articles/PMC12663885/). Payload limits (~4.7 kb) remain binding; compact Cas variants, dual vectors, or trans‑splicing strategies are required.

### Ex vivo electroporation in hematology

Ex vivo delivery of RNPs into autologous HSCs via electroporation is clinically mature and anchored by the first approved CRISPR therapy. The [**Innovative Genomics Institute’s 2025 clinical trials update**](https://innovativegenomics.org/news/crispr-clinical-trials-2025/) summarizes outcomes reported by regulators and companies for the ex vivo sickle cell disease and beta‑thalassemia program. Benefits have been durable in many recipients, though conditioning toxicity, manufacturing scale, and cost are persistent realities.

### VLPs and physical/field-based approaches

VLPs offer transient, nonviral delivery of RNPs with the potential for reduced immunogenicity, and physical methods (e.g., ultrasound/microbubble cavitation) provide local uptake boosts. As of 2025, these remain largely preclinical for CRISPR, with manufacturing scalability and consistency as active development topics.

| Modality | Clinical maturity | Typical target tissues | Payload characteristics | Immunogenicity/toxicity | Notable 2024–2025 insights |
| --- | --- | --- | --- | --- | --- |
| LNP (in vivo) | Phase 1–3 liver programs | Liver (systemic) | mRNA/RNP; large cargo | Infusion reactions; hepatic labs | FDA hold emphasizes hepatic safety protocols; robust protein knockdown signals |
| AAV (in vivo) | Ocular/CNS/local trials | Retina, ocular; localized CNS | ~4.7 kb (dual/split for CRISPR) | Anti‑AAV/anti‑Cas; persistence | Dual‑AAV co‑transduction retina data; dose and immunity management are key |
| Ex vivo electroporation | Approved therapy | HSCs; immune cells | RNP/plasmid (high control) | Conditioning toxicity dominates | Durable clinical benefits; GMP scale/cost constraints |
| VLPs | Preclinical | Targeted cells, nondividing | RNP payloads | Lower than viral (potential) | Transient delivery; manufacturing consistency under development |
| Physical/field-based | Preclinical/local | Local tissues | No strict size limit | Device/field effects | Local specificity; early translational steps |



![/content-api/uploads/originals/c4f93624-61a3-4ee9-82e1-02d97b8c0ead.jpg](/content-api/uploads/originals/c4f93624-61a3-4ee9-82e1-02d97b8c0ead.jpg)


## Clinical Milestones Worth Your Bench Time

Casgevy (exagamglogene autotemcel) remains the only approved CRISPR therapy, using ex vivo Cas9 editing of HSCs to upregulate fetal hemoglobin for sickle cell disease and transfusion-dependent beta‑thalassemia. Reported outcomes in 2024–2025 updates summarize durable benefits; see IGI’s synthesis and regulatory context in [**IGI’s CRISPR clinical trials 2025 update**](https://innovativegenomics.org/news/crispr-clinical-trials-2025/). Where peer‑reviewed phase 3 publications are still pending, treat quantitative claims as regulator/company‑attributed.

In vivo liver programs continue to advance, while emphasizing safety discipline. The FDA’s hold on two ATTR phase 3 trials in October 2025, following a grade‑4 hepatic event, highlights actionable takeaways: cautious escalation, predefined stopping rules, and comprehensive off‑target analyses with final clinical material.

Adenine base editing of PCSK9 has shown promising early human signals delivered via LNP. Topline 2025 data—mean LDL‑C reductions of roughly 50% in small cohorts at certain doses—were reported via reputable news summaries and company releases; see cohort context in [**TCTMD’s Heart‑2 topline coverage (2025)**](https://www.tctmd.com/news/topline-data-point-promise-verve-102-gene-editing-therapy). As peer‑reviewed manuscripts emerge, expect refinements in dose selection and safety profiles.

Beyond these, first‑in‑human experiences are widening: Cleveland Clinic reported a phase 1 CRISPR lipid‑lowering infusion with short‑term safety and efficacy signals; read the overview in [**Cleveland Clinic’s newsroom update (2025)**](https://newsroom.clevelandclinic.org/2025/11/08/cleveland-clinic-first-in-human-trial-of-crispr-gene-editing-therapy-shown-to-safely-lower-cholesterol-and-triglycerides).

## Assays, Off‑Targets, and Potency: What Regulators Expect Now

Assay design has matured into a regulatory discipline. The FDA’s “Human Gene Therapy Products Incorporating Human Genome Editing; Guidance for Industry” (April 2024) sets explicit expectations for on‑ and off‑target characterization, assay sensitivity, and clinical material testing. Sponsors should combine unbiased discovery (e.g., GUIDE‑seq, CIRCLE‑seq, Digenome‑seq) with targeted deep sequencing at predicted sites, quantify allele frequencies, and present acceptance criteria aligned to mechanism of action. See framework details on the **FDA’s CGT guidances page (2024)**.

Potency must be justified with orthogonal assays tied to clinical effect: percent on‑target editing by NGS, protein level changes (e.g., TTR, PCSK9), and functional cell assays. CMC expectations encompass identity, purity, potency, stability, impurity control, and process validation for both editor and delivery vehicle. Long‑term follow‑up remains essential when persistence or integration risks are present, with typical expectations approaching 15 years for certain vector classes.

## AI‑Enabled CRISPR Design and Analysis: Practical Wins, Real Limits

AI is moving from novelty to workflow helper. A 2025 study from Stanford/Princeton/DeepMind reports agentic planning that outperformed general LLM baselines across CRISPR experiment design, including system selection, gRNA design, delivery suggestions, validation experiments, and troubleshooting—validated against expert benchmarks. For an accessible overview and links to the paper, see [**Stanford Medicine’s 2025 news on AI‑powered CRISPR tools**](https://med.stanford.edu/news/all-news/2025/09/ai-crispr-gene-therapy.html). These tools are best used as accelerants under expert oversight, especially in rare or complex contexts.

Where does AI fit today? Think of gRNA pre‑screening, assay sensitivity planning, off‑target risk triage, and protocol drafting to standardize documentation. It won’t replace wet‑lab validation or regulatory assay requirements, but it can compress iteration cycles and surface edge cases earlier.

## Failure Modes and Lessons You Can Use Tomorrow

- AAV inflammatory events and immunity: Screen for preexisting anti‑AAV and anti‑Cas antibodies, define prophylaxis, and enforce dose discipline. Local administration with matched capsids can reduce systemic exposure but doesn’t eliminate risk.
- LNP hepatic lab changes: Set thresholds for transaminases and bilirubin with predefined dose interruptions; ensure post‑infusion monitoring windows capture delayed lab signals. Conservative escalation and clear stopping rules are non‑negotiable in 2025.
- Ex vivo realities: Conditioning toxicity often drives risk more than editing itself. Plan for supportive care, transparent eligibility criteria, and manufacturing slots that accommodate re‑scheduling without compromising product quality.

## Two Implementation Workflows to Borrow

### In vivo LNP liver program: candidate to clinic

Select candidate lipids and ratios based on prior hepatocyte uptake evidence; design gRNAs with AI assistance and orthogonal off‑target prediction. Formulate and QC for size, PDI, encapsulation, and stability; stress‑test for aggregation. In preclinical studies, confirm biodistribution and editing in the target tissue, then combine unbiased off‑target discovery with targeted deep sequencing. Map potency to mechanism (e.g., percent editing vs. circulating protein reduction) and define hepatic safety thresholds with dose‑interruption rules. In clinical design, escalate cautiously, collect intensive hepatic labs post‑infusion, and pre‑register stopping rules; incorporate long‑term follow‑up.

### Ex vivo HSC program: release criteria and monitoring

Optimize cell collection/enrichment and electroporation parameters (buffer composition, pulse profile). Establish on‑target efficiency by NGS and run unbiased off‑target discovery, then lock targeted panels for batch release testing. Define identity, purity, potency, and stability criteria for the edited cell product; validate process controls and chain of custody. Coordinate conditioning regimens with risk mitigation, and set post‑engraftment monitoring for durability, hematologic recovery, and adverse events.

## Where Proprietary Delivery Data Moves the Needle (And How to Engage)

If head‑to‑head clinical comparisons are scarce, how do you choose a delivery route for a specific tissue and payload with confidence? Extrahepatic programmable LNP claims are promising but largely preclinical; VLPs and field‑based methods need human metrics. What changes the calculus is access to rigorous, comparative delivery datasets—covering efficiency, biodistribution, toxicity, and manufacturability—generated under standardized assays and materials.

Here’s the deal: proprietary delivery benchmarking that applies the FDA’s assay expectations (discovery + targeted quant on final clinical material) can de‑risk program decisions before expensive scale‑up. It helps answer practical questions like: Which formulation gives the best editing-to-toxicity ratio in a given tissue? Where do off‑target signals concentrate, and how sensitive is our detection? What manufacturing parameters most affect lot‑to‑lot consistency?

If you’re exploring extrahepatic LNPs, comparing AAV capsid options for local administration, or evaluating transient VLP routes, a data-backed collaboration accelerates decisions. Our partnership team can share comparative delivery findings, assay frameworks, and workflow templates to fit your indication and constraints—without hype, with reproducible methodology.

- Interested in comparative delivery data or a joint benchmarking study? Reach out to discuss a focused collaboration pathway with our technical leads.

## A concise wrap and next steps

Delivery choices—not just editor chemistry—now determine translational success. 2024–2025 data reinforce LNP for liver, AAV for local/nondividing tissues, and ex vivo electroporation for hematology, while VLPs and physical methods advance preclinically. Regulatory assay discipline (discovery + targeted quant on final material), potency/CMC alignment to mechanism, and long‑term follow‑up are foundational. AI can streamline design and documentation, but expert oversight remains essential.

If you need comparative delivery benchmarks, assay frameworks tailored to your indication, or workflow support for trial readiness, contact our partnerships team. Let’s align on a data plan that moves your program forward—safely, efficiently, and transparently.
', 'Explore authoritative CRISPR gene editing best practices, delivery strategies, clinical translation, and AI workflows. Data-driven guidance for sci...'),
    ('1764993088615', 'Best Practices for CRISPR+AI in Target Discovery Economics', 'Admin', '/content-api/uploads/originals/79b28632-397d-4913-a45c-86172ae8df34.jpg', '2025-12-06T00:00:00.000Z', '2026-06-18T20:31:02.302Z', '## How CRISPR+AI Is Rewriting Target Discovery Economics — Lessons from the AstraZeneca–Algen Tie‑Up

If you run R&D in immunology or complex inflammatory disease, the cost of a bad target is measured in years and eight figures. The AstraZeneca–Algen partnership, valued at up to $555M, is a signal: integrated CRISPR functional genomics plus AI isn’t just a lab curiosity—it’s becoming an economic lever for enterprise drug discovery.

Here’s the core idea. By running perturbation experiments in human, disease‑relevant cell systems and feeding those single‑cell readouts into continuously learning models, you compress the time to decision, increase the fraction of causal, human‑relevant targets, and create an audit‑ready data backbone that stands up to regulatory scrutiny. Think of it as moving from “best‑guess targets and long validation tails” to “evidence‑first shortlists with fast confirm/kill cycles.”

## The economic levers CRISPR+AI actually moves

Three levers matter for your portfolio economics: decision speed, target quality, and governance overhead. CRISPR pooled screens, tuned for loss‑ and gain‑of‑function in the right cell context, can collapse hypothesis cycles from months to weeks in defined use cases. Single‑cell readouts reduce the ambiguity that traditionally inflates rework, while AI models trained on perturbation–phenotype mappings prioritize hits with better translational odds. When you add risk‑based model documentation and data integrity controls, you also cut down the compliance friction that often slows cross‑functional go/no‑go.

Below is a compact view of where the numbers tend to shift. Ranges are directional and program‑dependent, not guarantees.

| Metric | Legacy discovery (typical) | With CRISPR functional genomics + AI | Notes |
| --- | --- | --- | --- |
| Screen→shortlist cycle time | Months per iteration | Weeks in defined contexts | Driven by pooled CRISPR + high‑throughput single‑cell readouts |
| Hit quality (orthogonal pass rate) | Low‑to‑moderate | Higher, due to causal inference | Expect gains when orthogonal validation is built‑in |
| False‑positive spend | High rework burden | Lower, earlier kill of non‑causal hits | Savings realized in downstream assays/dev work |
| Documentation burden | Fragmented, manual | Centralized, audit‑ready | If pipelines are validated and versioned |
| Translational relevance | Variable | Improved in human‑relevant systems | Still requires disease‑context rigor |



![/content-api/uploads/originals/79b28632-397d-4913-a45c-86172ae8df34.jpg](/content-api/uploads/originals/79b28632-397d-4913-a45c-86172ae8df34.jpg)


## What the AZ–Algen deal really signals

Public coverage confirms a multi‑target collaboration in immunology worth up to $555M in upfront, near‑term, and milestone payments, with AstraZeneca receiving exclusive rights to develop and commercialize programs from discovered targets. Precise splits and the number of targets aren’t disclosed, but the emphasis is unmistakable: human‑relevant functional genomics tied to AI modeling. The detailed partnership note in 2025 at CRISPR Medicine News underscores AI‑powered functional genomics for immunology and highlights human‑relevant models as a differentiator: [**“Algen Biotechnologies announces multi‑target partnership to advance AI‑powered drug discovery in immunology” (2025)**](https://crisprmedicinenews.com/press-release-service/card/algen-biotechnologies-announces-multi-target-partnership-to-advance-ai-powered-drug-discovery-in-imm/). BioSpace provides a concise summary of the total potential payment size and exclusivity contours, while noting limited disclosure on terms: [**“AstraZeneca makes another AI deal with $555M Algen alliance” (2025)**](https://www.biospace.com/business/astrazeneca-makes-another-ai-deal-with-555m-algen-alliance).

For R&D leaders, the takeaway isn’t the headline number. It’s that enterprise buyers are pricing the ability to generate decision‑grade, human‑relevant target evidence—fast—and to do it with a governance posture that can scale.

## The 5‑Point Executive Playbook

1. Scope for translational fidelity first Define disease context and primary cell systems up front; decide whether CRISPRko, CRISPRi/a, or a combination best matches your biology questions. Pre‑register what “decision‑grade” means: replicate thresholds, single‑cell modalities, and the orthogonal assays you’ll accept as confirmation. Design your metadata and data standards before a single guide is cloned.
2. Design screens with power and validation baked in Use multiple independent sgRNAs per gene (e.g., 4–10) and plan coverage and MOI for single‑copy delivery where appropriate. Require replicate concordance before hit calling and commit to orthogonal validation paths (CRISPRi/a vs CRISPRko, rescue experiments, targeted sequencing). For practical methods guidance, see the peer‑reviewed overview in [**Nature Reviews Methods Primers on high‑content CRISPR screening (2021)**](https://www.nature.com/articles/s43586-021-00093-4).
3. Demand model credibility, not just accuracy Treat AI components as decision‑support tools that must be reliable, documented, and monitored. Align with the U.S. FDA’s 2025 draft guidance on AI used to support regulatory decisions—risk‑based credibility, transparency, and lifecycle documentation are center stage: [**FDA’s “Considerations for the Use of AI to Support Regulatory Decision‑Making for Drug and Biological Products” (2025)**](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological). In Europe, regulators advise a risk‑based approach with human oversight and traceability across the lifecycle; consult official guidance hubs when planning.
4. Govern the platform like an enterprise system Use a framework that procurement, QA, and legal can rally around. The NIST AI Risk Management Framework (RMF) offers a practical backbone—Govern, Map, Measure, Manage—for vendor due diligence and ongoing oversight. Ask for model cards, data lineage, bias/robustness assessments, and incident logs; require versioning and audit trails for both wet‑lab and ML pipelines. Reference: [**NIST AI RMF 1.0 and Playbook (2023)**](https://www.nist.gov/itl/ai-risk-management-framework).
5. Structure your pilot for measurable economics Write the pilot like a mini‑SLA: define cycle‑time KPIs (screen‑to‑validated‑hit), quality KPIs (orthogonal pass rate), integrity KPIs (audit trail completeness), and translational KPIs (confirmation in human‑relevant systems). Set clear go/no‑go gates and milestone triggers that map to decision economics—what gets prioritized, paused, or killed.

Disclosure/brand note (vendor help, no claims): Agentum AI operates a curated marketplace and integration practice that helps R&D teams evaluate and implement enterprise‑grade AI agents and platforms. If you need a neutral, field‑tested vendor checklist and implementation support for CRISPR+AI pilots, Agentum can provide templates and facilitation without prescribing a specific vendor.

## Risks, pitfalls, and how to de‑risk

CRISPR screens can be deceived if underpowered or poorly controlled. Guide efficacy varies; without enough independent guides per gene and proper coverage, you’ll inflate noise and waste follow‑up spend. DNA damage artifacts from nuclease‑based knockouts can masquerade as biology; using CRISPRi/a alongside CRISPRko, and running rescue experiments, helps separate mechanism from artifact. Off‑target effects remain a real risk—pair in silico predictions with empirical assays and targeted deep sequencing on both on‑ and predicted off‑target loci. On the AI side, black‑box models that lack documentation and monitoring can create compliance drag and trust gaps with governance teams. The fix is straightforward but non‑negotiable: pre‑specify validation gates, enforce audit trails, and require model transparency artifacts before any hit advances.

A final point on reproducibility. Require biological replicates with explicit correlation thresholds before hit calling, and keep a hard line on data integrity (ALCOA++). If your data and model artifacts aren’t versioned and reviewable, any short‑term speed win will be paid back—with interest—during diligence or regulatory interactions.

## Your next move

Run a tightly scoped pilot, not a sprawling platform bet. Start with one disease context, one prioritized assay modality, and a clear success definition tied to decision economics. If you’d like a ready‑to‑use evaluation aid, download the Enterprise AI Vendor Checklist to pressure‑test prospective partners on scientific validity, model credibility, interoperability, and governance. It’ll help you move faster—and with fewer expensive surprises.
', 'Explore how integrated CRISPR functional genomics and AI models transform target discovery economics—practical workflow, validation, and vendor eva...'),
    ('1766434897025', 'Reflecting on 2025: Gratitude and Growth at BioArk Technologies', 'Admin', '/content-api/uploads/originals/c9e2d152-a7c8-4c8a-b249-16fc1977af11.png', '2025-12-22T00:00:00.000Z', '2026-06-18T20:31:02.301Z', 'As the year comes to a close, we find ourselves looking back with immense gratitude. It has been a landmark year for **BioArk Technologies**, and we know we didn’t get here alone.


We want to extend a heartfelt thank you to:

- **Our Partners** 🤝: For your collaboration and shared vision in driving innovation forward.
- **Our Customers** 💼: For your continued trust in our solutions and your commitment to excellence.
- **Our Employees** 🌟: For your tireless dedication, creativity, and passion. You are the heart ❤️ of everything we do.


![/content-api/uploads/originals/7b903876-0175-49fd-a69c-15634ca4ff27.png](/content-api/uploads/originals/7b903876-0175-49fd-a69c-15634ca4ff27.png)



Wishing our entire community a joyful holiday season and a prosperous New Year. We look forward to reaching even greater heights together in 2026!


<iframe
  width="640"
  height="360"
  src="https://www.youtube.com/embed/6tw_JVz_IEc"
  title="YouTube video player"
  frameborder="0"
  allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture"
  allowfullscreen>
</iframe>

', 'As 2025 comes to a close, we at BioArk Technologies pause to express our heartfelt gratitude. Thank you to our partners, customers, and employees f...'),
    ('1759625715717', 'Exciting Progress in AAV-Delivered CRISPRa Therapies for Neurological Disorders', 'Admin', '/content-api/uploads/originals/69e63ad9-9977-4ea9-b237-90b8f611af7b.png', '2025-10-05T00:00:00.000Z', '2026-06-18T20:31:02.302Z', '🚀 Researchers at **@University of California, San Francisco (UCSF)** have made a breakthrough in **cis-regulatory therapy (CRT)** for neurological diseases.  

🧠 **SCN2A haploinsufficiency** is among the most common causes of neurodevelopmental disorders, often linked to **autism spectrum disorder**, **intellectual disability**, and **refractory epilepsy**.  

In this study, the team applied **CRISPR activation (CRISPRa)** to upregulate the functional *SCN2A* allele in *Scn2a* haploinsufficient (*Scn2a+/−*) mouse models. To overcome AAV’s limited packaging capacity, the researchers used a **minimal CRISPRa system (dSaCas9-VP64 and SasgRNA)**, packaged separately and co-delivered via **AAV-DJ** and **AAV-PHP.eB**.  

After just four weeks, treated mice exhibited **significant improvements in neuronal electrophysiological function** and **behavioral outcomes**, including **reduced seizure activity**.  

This study underscores the **therapeutic potential of combining CRISPRa with AAV delivery systems**, paving the way for **next-generation CRT-based neurological therapies**.  

---

## 🔬 Looking for CRISPRa Solutions?

If you need an **all-in-one system** to efficiently deliver CRISPRa components, our team can help. We offer:  
- **All-in-One Lentiviral Vectors**  
- **Virus-Like Particles (VLPs)**  
- **Customized Research Project Support**

👉 [Explore our services](https://bioarktech.com/products/crispr-activation)  

📩 **Reach out anytime** — we’d love to support your next breakthrough.



![/content-api/uploads/originals/6165f8bc-16a6-44d5-a2bd-74dc02a41502.png](/content-api/uploads/originals/6165f8bc-16a6-44d5-a2bd-74dc02a41502.png)


![/content-api/uploads/originals/3d20efde-5219-4f2a-9fbf-422699a8046b.png](/content-api/uploads/originals/3d20efde-5219-4f2a-9fbf-422699a8046b.png)




', 'Researchers at the University of California, San Francisco (UCSF) have demonstrated a powerful AAV-delivered CRISPRa approach to restore SCN2A expr...'),
    ('1758252345878', 'Bespoke CRISPR Base Editing for MSMDS: Promising Preclinical Results', 'Admin', '/content-api/uploads/originals/dcc9f1fc-6574-49d3-b00a-5cf7e20d4318.png', '2025-09-19T00:00:00.000Z', '2026-06-18T20:31:02.302Z', '
Another single-gene disorder may have a promising therapeutic path. **Multisystemic Smooth Muscle Dysfunction Syndrome (MSMDS)** is a rare disease that primarily affects children and is often driven by the **ACTA2 R179H** variant.

👩‍🔬 A team at **Harvard Medical School**—including **Mark E. Lindsay**, **Benjamin P. Kleinstiver**, and **Patricia L. Musolino**—engineered a **bespoke adenine base editor (ABE8e-eVRQR)** and delivered it via **AAV9** or **AAV-PR** to correct the pathogenic allele *in vivo*. In preclinical studies, the editor demonstrated high precision and editing efficiency. In a mouse model carrying the same mutation, treatment with **AAV-PR ABE** extended **median survival to 22.6 weeks**, whereas untreated MSMDS mice **died by 8 weeks**.

💡 These findings underscore the potential of base editing to correct single-nucleotide variants without inducing double-strand breaks. Further study is needed before clinical translation.

📄 Full paper (Nature): <https://www.nature.com/articles/s41551-025-01499-1.epdf>



![/content-api/uploads/originals/45673054-6723-4860-8e63-146c1ecbd07a.png](/content-api/uploads/originals/45673054-6723-4860-8e63-146c1ecbd07a.png)


![/content-api/uploads/originals/a9f05b68-b2d4-428a-912b-0a13c9cf253c.png](/content-api/uploads/originals/a9f05b68-b2d4-428a-912b-0a13c9cf253c.png)




', 'Harvard researchers used a tailored adenine base editor to correct the ACTA2 R179H mutation in a mouse model of MSMDS. Treated mice lived a median...'),
    ('1758202051223', 'Explore the New BioArk Technologies Website', 'Admin', '/content-api/uploads/originals/ef42633c-9c40-48e7-9448-ff9bd9509652.png', '2025-09-18T00:00:00.000Z', '2026-06-18T20:31:02.302Z', '
**We are excited to announce that the BioArk Technologies website has been updated with new features and information.**

**BioArk Technologies** is an innovative biotechnology company specializing in advanced gene editing solutions. Our services include:

- **Molecular cloning** for precise DNA manipulation and construct design  
- **Viral packaging** (lentivirus, AAV, and related systems) for efficient gene delivery  
- **Stable cell line development** to support reliable research and therapeutic applications  
- **Comprehensive gene editing projects** for laboratories that need execution of complex workflows from design through validation  


As a rapidly growing company in the gene editing field, we are committed to bridging the gap between cutting-edge research and real-world applications. Our mission is to empower scientists and organizations with reliable tools and services that accelerate discovery, innovation, and translational breakthroughs.

To learn more or collaborate with us, please contact us at [support@bioarktech.com](mailto:support@bioarktech.com).

![/content-api/uploads/originals/ef42633c-9c40-48e7-9448-ff9bd9509652.png](/content-api/uploads/originals/ef42633c-9c40-48e7-9448-ff9bd9509652.png)


![/content-api/uploads/originals/ed0520f5-bdc2-4437-8b80-6d1e7e17d689.png](/content-api/uploads/originals/ed0520f5-bdc2-4437-8b80-6d1e7e17d689.png)


![/content-api/uploads/originals/297ef0ee-e894-4472-b9d1-a2e9e665bd06.png](/content-api/uploads/originals/297ef0ee-e894-4472-b9d1-a2e9e665bd06.png)


![/content-api/uploads/originals/49f85c3f-d48e-418f-a19e-001855430543.png](/content-api/uploads/originals/49f85c3f-d48e-418f-a19e-001855430543.png)


', 'BioArk Technologies has updated its website with new features and clearer service information. Discover our gene editing services, including molecu...'),
    ('1758198774140', 'Advancing Montgomery County’s Life Sciences: A BioArk Roundtable', 'Admin', '/content-api/uploads/originals/ea8b7938-57fb-44d0-be57-cca3f71c33d5.jpg', '2025-09-18T00:00:00.000Z', '2026-06-18T20:31:02.302Z', '
*BioArk recently hosted a gathering of regional leaders across biotech, AI, and public service to strengthen collaboration and investment in Montgomery County’s life sciences ecosystem.*

## Distinguished Guests
- **Judy Costello** — Director, Montgomery County  
- **Natcha (Lyn) Thawesaengskulthai** — Director, Montgomery County  
- **Weiming Yu** — CEO, Shanghai Gene Era Biotech  
- **Jingwen Xu** — CEO, EGFIE  
- **Marcy Wu** — CEO, SceneX AI  
- **Yongping Chen** — CRO; Expert in Vivo/Preclinical Pharmacology  
- **Dr. Shutong Yang** — Scientist, NIH  
- **Dr. Min Li** — Scientist, NIH/NIDDK  

This event provided a valuable opportunity to connect with scientists, biotech leaders, investors, AI innovators, and Montgomery County officials—all united by a shared commitment to advancing business, innovation, and investment in the region.

---

## Montgomery County’s Life Sciences Hub
Montgomery County—part of Maryland’s thriving life sciences cluster—is home to more than **300** life sciences companies and about **40,000** biotech professionals, making it the **third-largest biopharma cluster** in the United States.

We’re excited to continue fostering this community and look forward to seeing Montgomery’s biotech scene rise even higher.


![/content-api/uploads/originals/ea8b7938-57fb-44d0-be57-cca3f71c33d5.jpg](/content-api/uploads/originals/ea8b7938-57fb-44d0-be57-cca3f71c33d5.jpg)

![/content-api/uploads/originals/50a295bd-281b-4e4a-b06b-f4c78ff2a8c4.jpg](/content-api/uploads/originals/50a295bd-281b-4e4a-b06b-f4c78ff2a8c4.jpg)




', 'BioArk brought together county leaders, NIH scientists, and industry innovators for a focused conversation on advancing Maryland’s biohealth economy'),
    ('4', 'VLPs vs AAVs: ENVLPE+ Advances for CRISPR RNP and Prime Editing Delivery', 'BioArk Editorial Team', '/images/blog/Blog-4-20250617.png', '2025-06-17T00:00:00.000Z', '2026-06-18T20:31:02.302Z', 'Compared with adeno‑associated viruses (AAVs), virus‑like particles (VLPs) can deliver CRISPR ribonucleoproteins (RNPs) transiently with lower immunogenicity, flexible tropism via pseudotyping, and strong specificity. Remaining hurdles—RNP stability, packaging efficiency, and potency—are being addressed by new engineering strategies.

One such advance is ENVLPE+ (Cell: “Engineered nucleocytosolic vehicles for loading of programmable editors,” Truong, Geilenkeuser et al.), which improves packaging and delivery of prime editing effectors.

## What is ENVLPE+?
ENVLPE+ retools the Gag‑Pol framework and RNA scaffolds to increase cargo loading, stabilize pegRNA, and enhance budding and particle yield.

### Key components
- Optimized Gag–Pol fusion with enhanced nucleo‑cytoplasmic shuttling tags and a PCP–aptamer system to export RNPs to the cytoplasm for packaging.
- PP7–C4‑Q1 scaffold that stabilizes pegRNA and maintains complex integrity during assembly.
- Engineered coiled‑coil domains for Gag–PCP oligomerization, boosting budding and packaging efficiency.
- MiniENVLPE: a highly truncated design (<13% of HIV‑1 Gag) that preserves most editing/packaging function—promising for low‑immunogenicity vectors.

## Why it matters for prime editing
- Higher RNP/pegRNA stability improves edit rates while keeping exposure transient.
- Modular envelopes allow tissue targeting by pseudotyping.
- Truncated backbones point toward safer clinical translation.

## Research opportunities
1. All‑in‑one CRISPR VLPs that co‑deliver RNPs and donor DNA.
2. Systematically combine gRNA stabilization and Cas9 loading motifs for maximal potency.
3. MiniENVLPE‑based variants optimized for low immunogenicity.
4. Expanded pseudotype library to reach difficult tissues.

## Outlook
VLPs are emerging as a practical, safer alternative to integrating viral vectors for genome editing. With designs like ENVLPE+, the field is moving toward programmable, modular vehicles that can deliver prime editors with higher efficiency and better control.', 'ENVLPE+ boosts VLP packaging, stability, and delivery for prime editing, pointing to safer, modular gene therapy vectors.'),
    ('3', 'The Secret of PAM: Is It Essential for CRISPR Targeting?', 'BioArk Editorial Team', '/content-api/uploads/originals/c4c6cfc9-337e-4c4a-8528-7e59ef48646e.jpg', '2025-05-07T00:00:00.000Z', '2026-06-18T20:31:02.302Z', 'The Protospacer Adjacent Motif (PAM) is central to how many CRISPR systems recognize double‑stranded DNA (dsDNA). A recent Molecular Cell study (“Rapid Two-Step Target Capture Ensures Efficient CRISPR-Cas9-Guided Genome Editing,” Doudna, Bryant et al.) helps explain why PAM improves both speed and fidelity—and why PAM-relaxed variants like SpRY often lose efficiency while increasing off‑target risk.

## Why PAM helps Cas9
- PAM provides a quick “license to bind,” allowing Cas9 to rapidly sample DNA and reject non-target sites.
- Following PAM engagement, the duplex locally unwinds and seeds R‑loop formation, enabling stepwise RNA:DNA hybridization.

### A two‑step capture model (per Molecular Cell)
1. Priming: PAM-dependent docking lowers the energetic barrier for local unwinding.
2. Unwinding and propagation: The R‑loop initiates in the seed and extends to complete target capture.

This helps explain why SpRY, which binds many PAM-like contexts more strongly, can paradoxically hinder the unwinding/propagation step—slower editing and more off-targets despite broader nominal compatibility.

## Systems that do not require PAM
- ss targets: Cas14 (ssDNA) and Cas13 (RNA) do not need a strict PAM/PFS because the energetic barrier for unwinding is low or absent.
- Novel dsDNA systems without PAM: Tigr‑Tas (Zhang lab) and IS110 (Hsu lab) appear to use split/dual‑strand engagement rather than a single PAM-licensed site. Early editing efficiencies are low (e.g., <5%), suggesting a missing or inefficient priming step that future engineering may improve.

## Implications for next‑gen editors
- PAM is not merely a constraint; it’s part of a finely tuned balance between specificity and efficiency.
- PAM-relaxed nucleases need additional engineering to restore efficient unwinding and R‑loop propagation.
- New “no‑PAM” dsDNA systems may open fresh design space (cis vs. trans recognition modes), but require optimization to match practical editing performance.

Bottom line: Understanding the physics of target capture—PAM licensing, unwinding, and R‑loop kinetics—will guide safer, faster, and more versatile genome editors.', 'Recent studies reveal why PAM powers efficient Cas9 targeting and how next-gen systems may bypass PAM with new mechanics.'),
    ('2', 'CAR-T Therapies: Autologous, Universal, and In Vivo Approaches', 'BioArk Editorial Team', '/content-api/uploads/originals/5e93a812-829e-4195-8ff0-a5d05445295a.png', '2025-05-04T00:00:00.000Z', '2026-06-18T20:31:02.302Z', 'CAR-T therapies have transformed oncology, particularly for hematologic malignancies. Today’s development landscape spans three approaches—autologous, universal (allogeneic), and in vivo—each with distinct trade-offs in speed, cost, safety, and scalability.



![/content-api/uploads/originals/9de063b7-62f9-4b65-b7a7-f22a2e974ca8.png](/content-api/uploads/originals/9de063b7-62f9-4b65-b7a7-f22a2e974ca8.png)



## Three approaches at a glance
### Autologous (patient-derived)
- Pros: Proven efficacy; lower graft-versus-host risk; established regulatory precedents.
- Cons: Expensive and slow (bespoke manufacturing); variable starting material quality; challenging for rapidly progressing disease.

### Universal / Allogeneic (donor-derived, off‑the‑shelf)
- Pros: Batch manufacturing, lower cost of goods, faster turnaround; scalable logistics.
- Cons: Requires edits to reduce graft-versus-host and host-vs-graft rejection (e.g., TRAC, B2M, HLA); persistent immunogenicity risks.

### In vivo (edited inside the patient)
- Pros: Eliminates ex vivo manufacturing; potential for broad access and rapid deployment.
- Cons: Delivery remains the central challenge (viral vectors, VLPs, LNPs); dosing control and safety switching are active areas of research.

## How CRISPR is reshaping CAR-T
- Targeted integration: Site-specific insertion (e.g., TRAC, CCR5, PDCD1) improves expression uniformity and reduces insertional mutagenesis risk.
- Multiplex edits: Knockout of endogenous TCR and HLA to enable universal products; edits to resist exhaustion and immunosuppression.
- Built-in safety features: Inducible kill switches, suicide genes, and logic-gated CARs to mitigate severe adverse events.
- Epigenetic tuning: dCas-based regulators can modulate checkpoint genes and cytokines to improve persistence.

## Manufacturing, scale, and quality
- Autologous: vein-to-vein time is the bottleneck; orchestration and analytics (QC release) drive cost.
- Allogeneic: scale helps COGS, but genome engineering and release testing must assure product consistency.
- In vivo: analytics shift to biodistribution, persistence, and on/off-target profiling of the delivery system.

## Safety and regulatory considerations
- Genomic safety: minimize off-target edits; leverage validated safe-harbor loci and orthogonal nucleases.
- Immunogenicity: reduce alloreactivity and anti-product responses; consider humanized components.
- Pharmacology: dose control and reversibility (e.g., small-molecule gated CARs) for severe toxicity management.

## Outlook
CRISPR-enabled CAR-T is moving beyond “insert a CAR” to programmable cell therapies with multiplex edits and tunable function. In vivo editing could unlock true global scale if delivery hurdles are solved. Collaboration across delivery, editing, and manufacturing will determine how quickly the field expands from blood cancers into solid tumors.', 'From autologous to universal and in vivo CAR-T, CRISPR innovations are reshaping integration, safety, and scalability.'),
    ('1', 'STITCHR: A New Gene Editing Platform for Scarless Large-Fragment Integration', 'BioArk Editorial Team', '/images/blog/Blog-1-20250422.png', '2025-04-22T00:00:00.000Z', '2026-06-18T20:31:02.302Z', 'A Harvard-led team (Jonathan S. Gootenberg and Omar O. Abudayyeh) reported a programmable retrotransposon platform named STITCHR in Nature (“Reprogramming site-specific retrotransposon activity to new DNA sites”). The system couples CRISPR targeting with retrotransposon template-primed reverse transcription (TPRT) to enable scarless integration of DNA fragments ranging from single bases to >10 kb.

> Note: STITCHR is distinct from a similarly named “StitchR” approach that uses ribozyme-mediated mRNA trans-ligation to deliver large genes. The two technologies address different delivery challenges.

## What is STITCHR?
STITCHR reprograms an R2-like retrotransposon to insert payload DNA at CRISPR-specified genomic sites. A Cas9 H840A nickase introduces a single-strand nick to expose a 3'' end that primes reverse transcription of the donor template, leading to homology-guided, scarless integration.

### How it works (high level)
- Cas9 H840A nickase targets the site, generating a nick and a 3'' OH for priming.
- The retrotransposon reverse transcriptase extends from the nick into the donor template.
- Homology sequences guide precise ligation and completion, yielding seamless integration.

## Why it matters
- Scarless, seamless insertion up to ~12.7 kb: expands edits beyond the ~<500 bp typical for base/prime editing.
- High targeting precision with low off-target activity: nickase + TPRT pairing improves specificity versus classical double-strand breaks.
- Cell-cycle independence: maintains activity even when division is blocked (e.g., doxorubicin), enabling edits in non-dividing cells like neurons.

## Key capabilities
- Single-nucleotide edits, short tags, and full-length gene replacement within one platform.
- Potential compatibility with diverse cell types and tissues.
- Modular donor design with homology handles for flexible targeting.

## Technical challenges and open questions
### 1) Deliverability and construct size
The current fusion payload is large (Cas9 ~4.1 kb + retrotransposon components ~3.6 kb), which complicates in vivo delivery. RNA-formulated versions and LNP delivery are being explored, though RNA typically shows lower efficiency than plasmid/viral methods. A complementary direction is mRNA trans-ligation (the separate StitchR line of work) to handle very large cargos.

### 2) Mechanism: second-strand synthesis and completion
Details of in vivo second-strand DNA synthesis during homology-guided TPRT remain to be clarified. Better mechanistic insight should improve efficiency and fidelity.

### 3) Efficiency evolution
Homology-directed TPRT alone can be <1% but rises to ~3–11% when paired with Cas9 H840A in STITCHR. There is room to engineer both the TPRT module and CRISPR partner for higher rates.

## Early applications to watch
- Precise knock-ins for reporter tags and epitope fusions.
- Scarless correction or replacement of disease alleles.
- Installation of complex gene circuits without residual sequence scars.

## Outlook
STITCHR adds a much-needed option for large, precise, and potentially cell-cycle-agnostic integrations. Continued work on delivery (smaller constructs, RNA/LNP), mechanistic tuning, and donor design should determine how quickly the platform moves toward preclinical use.

', 'Harvard-led team unveils STITCHR, enabling scarless insertion up to 12.7 kb with high precision and cell-cycle independence.');

SELECT setval(pg_get_serial_sequence('public.blog', 'id'), COALESCE((SELECT MAX("id") FROM public."blog"), 1), true);

SET session_replication_role = DEFAULT;

COMMIT;
